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1.1 Review of the Literature  
 
Respiratory diseases cause major problems for pig herds all over the world. Enzootic 
pneumonia (EP) is one of the most important respiratory diseases in pigs. It is highly 
prevalent and causes considerable economic losses for both pig producers and the entire 
industry. The losses are mainly due to decreased performance of the pigs and increased 
antimicrobial use (Maes et al., 2008). 
Mycoplasma hyopneumoniae (M. hyopneumoniae) is the primary etiological agent of 
EP (Maes et al., 1999), and it is one of the main pathogens involved in the porcine respiratory 
disease complex (PRDC) (Thacker and Minion, 2010). Apart from infections with M. 
hyopneumoniae, PRDC results from infections with other bacterial (Actinobacillus 
pleuropneumoniae, Haemophilus parasuis, Pasteurella multocida, Streptococcus suis and 
Bordetella bronchiseptica) and viral (porcine reproductive and respiratory syndrome virus – 
PRRSV, porcine circovirus type 2, Aujeszky’s disease virus, swine influenza virus – SIV and 
porcine respiratory coronavirus) pathogens. PRDC is clinically characterized by coughing, 
retarded growth rates, inefficient feed conversion, anorexia, fever and dyspnea (Thacker and 
Minion, 2010). Although animals of all ages are susceptible to M. hyopneumoniae infection, 
animals in the growing and finishing phase are mostly affected. However, in herds without 
immunity, clinical disease following M. hyopneumoniae infections can affect pigs from all 
age groups, including suckling pigs and breeding animals (Sibila et al., 2007). 
Several methodologies are used to diagnose infections caused by M. hyopneumoniae. 
Clinical signs and pathological lesions are used for a presumptive diagnosis of EP, but further 
laboratory tests are required for a conclusive diagnosis. Although cultivation of M. 
hyopneumoniae is considered the gold standard for diagnosis, this method is not routinely 
used (Sibila et al., 2009). This is mainly because isolation of the pathogen in Friis medium is 
very difficult (Friis, 1975). In addition, the presence of other mycoplasma species may 
decrease the growth of M. hyopneumoniae, rendering their isolation even more difficult. Thus, 
failure to cultivate this organism from potentially infected animals cannot rule out the 
infection in the herd (Thacker, 2004). Immunofluorescence (IF) testing (Kobisch et al., 1978) 
is also frequently performed. Serologic tests are commonly used to monitor the health status 
of herds, but serology is not suited for diagnosis at the individual animal level (Sorensen et 
al., 1997). Currently, PCR testing is the most sensitive technique for detecting infections 
caused by M. hyopneumoniae (Calsamiglia et al., 1999).  
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The control of EP should focus on the optimization of management practices and 
housing conditions (Maes et al., 2008), the use of antimicrobial medication (Vicca et al., 
2004) and vaccination. Several commercial vaccines, consisting of the inactivated adjuvanted 
whole cells of M. hyopneumoniae are available and worldwide used. These vaccines have 
been proven to be effective in reducing the clinical signs, but only partial protection against 
the development of lesions is obtained (Haesebrouck et al., 2004). 
In this review, the characteristics of M. hyopneumoniae related to pathogenesis, 
immune response, lesions and control measures will be discussed. Furthermore, special 
emphasis will be placed on vaccination strategies, including the use of reverse vaccinology 
approaches. 
  
 
 
 
 
 
 
 
 
 
 
 
 
  
General introduction 
 
11 
 
1.1.1 Aetiology  
 
Mycoplasmas belong to the Mollicutes class and differ phenotypically from other 
bacteria by their diminutive size and absence of cell wall (Razin et al., 1998). Despite 
fundamental differences between mycoplasmas and other bacteria, many aspects of 
mycoplasmal molecular biology are similar to those of gram-positive bacteria (Thacker and 
Minion, 2010). Mycoplasmas are the smallest free-living self-replicating microorganisms. 
They also have small genomes (580 -1350 kb) with a high A + T content (about 70%). The 
whole genome of four M. hyopneumoniae strains (J, 232, 7448 and 168) has been sequenced 
(Liu et al., 2011; Minion et al., 2004; Vasconcelos et al., 2005).  
Because of their small genome, mycoplasmas undergo limited metabolism and have 
few biosynthetic pathways (Dybvig and Voelker, 1996). The lack of biosynthetic pathways 
implies that they need to obtain amino acids, purines and pyrimidines, and membrane 
components from their growth environment (Thacker and Minion, 2010). In addition, in vitro 
cultivation is quite fastidious, and most species have never been cultivated (Razin et al., 
1998). M. hyopneumoniae can be cultivated in vitro, but it requires serum enriched media 
such as Friis medium (Friis, 1975). The cultivation and isolation of M. hyopneumoniae are 
laborious, time-consuming and often not successful, so isolation is not used for routine 
diagnosis. Moreover, there is frequent contamination with other mycoplasmas such as M. 
hyorhinis (present in the respiratory tract of pigs) and M. flocculare (a non-pathogenic species 
that has similarities with respect to morphology, growth and antigenicity of M. 
hyopneumoniae) (Thacker and Minion, 2010). 
The fastidious nature of mycoplasmas and the lack of genetic systems to elucidate 
protein structures and functions have hampered understanding of their biology. In addition, 
studies suggest that mycoplasmas have complex systems of recombination that are able to 
create a high rate of antigenic diversity (Dybvig and Voelker, 1996). Indeed, Mycoplasma 
species have developed strategies to vary their surface topography to avoid detection and 
eradication by the host immune response (Browning et al., 2011). A previous study has 
indicated a complex transcriptional organization of the M. hyopneumoniae genome and 
suggested the likely existence of yet unknown mechanisms involved in transcriptional 
regulation (Siqueira et al., 2011). M. hyopneumoniae can produce adhesins, modulins, 
aggresins and impedins that allow adhesion and modulation of the host immune system (Asai 
et al., 1996; Henderson et al., 1996; Muneta et al., 2008). Besides this, studies revealed that 
surface antigens of M. hyopneumoniae are proteolytically processed upon translocation across 
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the membrane (Bogema et al., 2011; Burnett et al., 2006; Djordjevic et al., 2004; Wilton et al., 
2009). The ability of M. hyopneumoniae to selectively cleave its secreted proteins provides 
this pathogen with a remarkable capacity to alter its surface architecture. 
Molecular techniques demonstrated that M. hyopneumoniae shows a large diversity at 
genomic (Stakenborg et al., 2006; Strait et al., 2008) and proteomic level (Calus et al., 2007). 
Vicca et al. (2003) showed that there are also differences in virulence. These authors 
classified isolates as low, moderately and highly virulent, based on the outcome of 
experimental infections. Villarreal et al. (2011a) demonstrated that infection with low virulent 
M. hyopneumoniae isolates did not prevent infection and disease against a subsequent 
infection with a highly virulent isolate. However, further research is necessary to investigate 
the clinical importance of these differences between isolates. 
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1.1.2 Pathogenesis 
 
M. hyopneumoniae is a host specific pathogen that only infects pigs. The pathogenesis 
and especially possible virulence factors of M. hyopneumoniae are not yet fully known.  
 M. hyopneumoniae may infect animals via the inhalation of muco-respiratory droplets 
expelled during bouts of coughing from M. hyopneumoniae-infected animals (Desrosiers, 
2001). Upon inhalation, M. hyopneumoniae must overcome the mucociliary escalator and 
transverse layers of heavily glycosylated mucins. These are produced as decoys for bacterial 
adhesins that exploit surface glycoconjugates and extracellular matrix components during 
colonization. M. hyopneumoniae adheres to the ciliated respiratory epithelia where it initially 
causes ciliostasis, destruction of cilia and possibly epithelial cell death (Debey and Ross, 
1994).  
The ability to adhere tightly to respiratory cilia is a key strategy to overcome the 
mucociliary host defense (Figure 1) (Tajima and Yagihashi, 1982; Zhang et al., 1994).  
 
 
Figure 1: Transmission electron microscopy images of lung tissue from a pig infected with 
M. hyopneumoniae. Mycoplasma organisms are seen in close association with cilia (Sarradell 
et al., 2003). 
 
Adhesion of the organism to tracheal, bronchial and bronchiolar epithelium, 
stimulation of a prolonged inflammatory reaction, suppression and modulation of the innate 
and adaptive immune responses are recognized as important steps in the pathogenesis of 
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infections with this organism (Thacker and Minion, 2010). As a result, infected animals are 
more susceptible to infections with other respiratory pathogens (Sorensen et al., 1997). 
The exact method of adherence of the organism to the cilia has not been fully 
elucidated. A number of proteins involved in adherence have been identified. M. 
hyopneumoniae multifunctional adhesins belonging to the P97/P102 families include Mhp182 
(P102), Mhp183 (P97), Mhp 493 (P159), Mhp 494 (P216), Mhp 683 (P135), Mhp 271, Mhp 
107 and Mhp 108 (P116). These adhesins are expressed during broth culture (Burnett et al., 
2006; Djordjevic et al., 2004; Pinto et al., 2007a; Wilton et al., 2009; Zhang et al., 1995) and 
in vivo in experimentally infected pigs (Adams et al., 2005). Fragments of P97 (Zhang et al., 
1995), P216 (Wilton et al., 2009), P102 (Seymour et al., 2012), Mhp271 (Deutscher et al., 
2012), Mhp107 (Seymour et al., 2011) and Mhp683 (Bogema et al., 2011) have been shown 
to bind porcine cilia. 
P97 is the first identified adhesin of M. hyopneumoniae. It recognizes receptors 
present on the cilia of respiratory epithelial cells and is considered a virulence factor (Zhang 
et al., 1995). The C-terminal portion of P97, identified as R1, is responsible for cilium 
binding. Eight R1 repeating units are required for this binding. Variation due to the addition 
or subtraction of repeated amino acids may result in alteration of the protein, which may 
interfere with the recognition by the immune system (Minion et al., 2000). However, other 
factors or additional proteins are also required for adherence (Hsu and Minion, 1998).  
The P102 protein is part of the same operon as P97 and its expression also appears to 
be associated with binding of the pathogen to cilia. Studies also suggest its participation in 
virulence since it is expressed in vivo during infection (Adams et al., 2005). Apart from these 
findings, the role of P102 and its paralogs has not been previously elucidated. Seymour et al. 
(2010) examined the surface expression and proteolytic processing of the P102 paralog P116, 
an extensively processed protein in M. hyopneumoniae strain 232. The results suggest that this 
protein is a multifunctional virulence determinant involved in the M. hyopneumoniae disease 
process.  
Indeed, P97/P102 paralog family members on the cell surface of M. hyopneumoniae 
are targets of endoproteolytic processing events that generate a substantial combinatorial 
repertoire of cleavage fragments (Bogema et al., 2011; Deutscher et al., 2012; Wilton et al., 
2009), suggesting that these endoproteolytic fragments might influence how M. 
hyopneumoniae interacts with its host. Endoproteolytic processing is a well-known 
mechanism used by bacterial pathogens to convert immature pre-proteins into mature 
functioning molecules. However, in the M. hyopneumoniae P97/P102 adhesin families, 
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posttranslational cleavage is extensive and unorthodox. Most of the P97/P102 family 
members previously examined undergo at least one cleavage event and in some cases two or 
more cleavage events (Bogema et al., 2011; Burnett et al., 2006; Djordjevic et al., 2004; Pinto 
et al., 2007a; Pinto et al., 2009; Wilton et al., 2009). Recently, a protease has been identified 
in M. hyopneumoniae which is responsible for processing the P97 and P102 family of cilium 
adhesins. It recognizes a peptide motif with a sequence similar to TTKF↓QE. This finding has 
facilitated the prediction of cleavage sites among members of these families (Bogema et al., 
2011). However, the biological rationale for cleavage and the protease (s) responsible are not 
yet determined. Endoproteolytic processing significantly increases surface protein diversity 
by altering the presentation of functional domains on the cell surface and may be a 
mechanism used to regulate the adhesion to host tissues, potentiate host cell invasion, and 
avoid immune clearance (Bogema et al., 2012).  
P102 and P97 are proteins with multifunctional binding abilities, which are also able 
to recruit plasminogen and fibronectin to the surface of M. hyopneumoniae. Binding of 
plasminogen and fibronectin to the surface of M. hyopneumoniae is dose dependent and 
saturable (Deutscher et al., 2012; Seymour et al., 2011; Seymour et al., 2012). Plasminogen is 
freely available in the bronchoalveolar fluid of the porcine lung, and M. hyopneumoniae 
displays surface receptors that bind plasminogen in a process that facilitates conversion to 
plasmin by mammalian plasminogen activators (Seymour et al., 2012). Consequently, M. 
hyopneumoniae colonizing the ciliated epithelia is likely to sequester plasminogen on its cell 
surface and facilitates its conversion to plasmin. This process is likely to have ramifications 
for tissue invasion and systemic infection (Bogema et al., 2012).  
Although M. hyopneumoniae is primarily a respiratory pathogen, it has also been 
isolated from internal organs, suggesting that spread may occur via the lymphatic or blood 
circulation (Marois et al., 2007). The agent was re-isolated from the liver, spleen and kidneys 
of experimentally infected and contact pigs (Le Carrou et al., 2006; Marois et al., 2007) and 
M. hyopneumoniae DNA was detected in these same tissues (Woolley et al., 2012). However, 
this spread within the body appears to be transient and is likely not involved in the 
development of EP (Marois et al., 2007; Woolley et al., 2012). 
It has been shown that M. hyopneumoniae has a modulating effect on the immune 
system, although the nature of this modulation is not well understood (Simecka, 2005). 
Alveolar macrophages and lymphocytes, stimulated by M. hyopneumoniae, produce pro-
inflammatory cytokines that play a role in lung lesion development and lymphoid hyperplasia 
(Rodriguez et al., 2004). In general, mycoplasmas are capable of evading the host's natural 
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defenses. It is known that some pathogenic species use their genetic machinery to alter surface 
antigens, thus diverting the host immune response and allowing for chronic infection (Razin 
et al., 1998). 
Data generated by sequencing and comparative analysis of three strains of M. 
hyopneumoniae allowed the identification of strain-specific regions that may be related to 
pathogenicity (Minion et al., 2004; Vasconcelos et al., 2005). The presence of an integrative 
conjugal element (ICE) was revealed in two strains that were pathogenic (7448 and 232) and 
is absent in the non-pathogenic J strain. This result suggests that the ICE, as a mobile DNA 
element, is probably involved in genetic recombination events, which can be related to the 
host adaptation and pathogenicity of the strain. Nevertheless, the transference of ICE between 
cells remains to be demonstrated experimentally (Pinto et al., 2007b).  
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1.1.3 Immune response 
 
Immune responses in mycoplasma disease may be involved in pathogenesis. Although 
immunity is known to control and prevent infections, immune responses can also promote the 
inflammatory lesions associated with mycoplasma disease (Razin et al., 1998). The exact 
immune responses during infection of pigs with M. hyopneumoniae are not fully understood. 
Upon colonization of the respiratory epithelial cells with M. hyopneumoniae, there is an 
infiltration of mononuclear cells (macrophages and lymphocytes) in the perivascular, 
peribronchial and peribronchiolar areas and alveolar septa, as well as hyperplasia of the 
lymphoid follicles around the airways, resulting in a chronic and prolonged inflammatory 
response (Sarradell et al., 2003). Thus, the interactions between the host’s immune system and 
the mycoplasma are complex and ultimately determine resistance to infection and severity of 
disease (Simecka, 2005). 
 
Innate immune response 
Shortly after infection, mycoplasmas interact with the cells of the innate immune 
system such as phagocytes, macrophages and polymorphonuclear (PMN) cells. These cells 
are attracted by the release of immunogenic proteins and mediators during mycoplasmal 
infection (Sarradell et al., 2003). Histological lesions in the acute stage of M. hyopneumoniae 
infection are characterized by loss of respiratory cilia, exfoliation of ciliated cells, and 
accumulation of neutrophils and macrophages in and around airways. In the chronic stages, 
there is lymphoid hyperplasia or cuffing and thickening of the inter-alveolar septa (Goodwin, 
1965).  
The presence of inflammatory cytokines, the products of activated macrophages, 
suggests that mononuclear phagocytes, possibly alveolar macrophages, have an important role 
in the initiation of an inflammatory response. This can be histologically visible as soon as 7 
days after infection (Choi et al., 2006). M. hyopneumoniae can directly stimulate 
macrophages to produce pro-inflammatory cytokines or other factors that have potential to 
modulate phagocytic activity. Even though macrophages are a first line of defense in the 
innate immune system, they become less effective upon M. hyopneumoniae infection 
(Thacker and Minion, 2010). For example, alveolar macrophages collected from pigs infected 
with M. hyopneumoniae had significantly lower phagocytic capacity than macrophages from 
uninfected animals (Caruso and Ross, 1990). This decreased phagocytic capacity is likely 
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important in the reduced clearance of M. hyopneumoniae as well as other secondary bacterial 
pathogens (Thacker and Minion, 2010). 
Cytokines are vital components of both humoral and cell-mediated immune responses, 
and they exert their biological effects by binding to specific receptors on target cell 
membranes. Based on their properties, some cytokines can be generally classified as pro-
inflammatory cytokines (represented by IL-1, IL-6, interferon gamma (IFN-ɣ) and tumor 
necrosis factor alpha (TNF-α)) or as anti-inflammatory cytokines (represented by IL-10 and 
transforming growth factor beta (TGF-β)). They are very important mediators in both lung 
defense and inflammation, but their overall positive or negative effect on the host tissue can 
be difficult to predict because of the complexity of both cellular and tissue environments 
(Yang et al., 2004). 
The production of proinflammatory cytokines has been shown to be associated with 
the development of M. hyopneumoniae induced pneumonia. Increased levels of IL-1, IL-2, 
IL-6, IL-8, IL-12, IL-18, IFN-ɣ and TNF-α have been reported in M. hyopneumoniae-infected 
pigs (Asai et al., 1993; Asai et al., 1994; Choi et al., 2006; Lorenzo et al., 2006; Muneta et al., 
2006; Redondo et al., 2009; Rodriguez et al., 2007; Rodriguez et al., 2004; Thacker et al., 
2000a; Thanawongnuwech et al., 2004). Indeed, it is increasingly recognized that for many 
bacteria, induction of cytokines is a major virulence mechanism (Henderson et al., 1996). 
However, some mycoplasmas colonize the respiratory tract with no apparent clinical 
symptoms due to their capacity to downregulate NFκB or to induce anti-inflammatory 
cytokines such as IL-10, IL-13, or TGF-β. This illustrates the complex network of synergistic 
and antagonistic influences induced by mycoplasmas on cells of the immune system (Rottem, 
2003). Indeed, IL-10 levels are increased in the bronchoalveolar lavage (BAL) fluid 28 days 
after inoculation with M. hyopneumoniae (Thanawongnuwech and Thacker, 2003). 
In addition, different M. hyopneumoniae strains may vary in their effect on the pig's 
immune system, resulting in variations in the inflammatory cell responses in the lungs. Meyns 
et al. (2007) showed that more leukocytes were found in the lung tissue and more IL-1β and 
TNF-α were detected in BAL fluid after infection with a highly virulent (HV) strain compared 
to infection with a low virulent (LV) strain. It is possible that different strains of M. 
hyopneumoniae induce the production of cytokines to a different extent. The resulting 
inflammatory response will be determined by the intricate cross-talk of all cytokines involved, 
and this may lead to a different outcome for different strains (Razin et al., 1998). 
Mycoplasma can stimulate different cell types through the interaction with toll-like 
receptors (TLR), which recognize pathogen associated molecular patterns (PAMPs). This 
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recognition leads to the activation or modulation of subsequent immune and inflammatory 
responses. The exact mechanisms are not fully understood, but porcine TLR2 and TLR6 will 
recognize lipoproteins from the mycoplasma and stimulate cells. There are indications that 
blocking TLR2 and TLR6, the overproduction of proinflammatory cytokines, such as TNF-α, 
may be regulated. In addition, that the vaccination may reduce the expression of TLR6 
contributing to the prevention of mycoplasmal pneumonia in swine (Muneta et al., 2003; 
Regia Silva et al., 2011).  
 
Adaptive immune response 
T cells can be regarded as the key players of the adaptive immune system, serving as a 
link between the innate and adaptive immune system. Specific protective defense mechanisms 
consist of stimulation of cell-mediated immunity, opsonisation and phagocytosis of organisms 
and production of systemic as well as local anti-mycoplasmal antibodies. Antigen presenting 
cells (macrophages, dendritic cells, B cells) pick up the pathogens and subsequently process 
and present them to be recognized by pathogen-specific T cells. Once activated, T cells 
influence all arms of immunity. They are in charge of inducing and maintaining acquired 
immunity and generating memory lymphocyte populations (Jones and Simecka, 2003). 
The role of the cell mediated immunity in animals with mycoplasmal pneumonia is 
ambiguous. Suppression of the T-cell response achieved by thymectomy or injection of 
antithymocyte serum before infection resulted in the development of less severe microscopic 
lesions of pneumonia compared to immunocompetent infected pigs. However, M. 
hyopneumoniae could spread systemically as it was re-isolated from the spleen of a 
thymectomized pig (Tajima et al., 1984). These results suggest that a T-cell-dependent 
mechanism may be important in the development of pneumonia but it is also important in 
preventing the invasion and systemic spread of M. hyopneumoniae (Thacker and Minion, 
2010). Alterations to the cellular immune response clearly play an important role in the 
induction of the disease and the ability of the organism to persist in infected pigs. 
M. hyopneumoniae is able to persist for a long time within infected pigs, possibly by 
suppressing the efficacy of the immune response or by evading it. During the progression of 
the disease, M. hyopneumoniae-specific and non-specific IFN-ɣ and IL-10 cytokine responses 
become inhibited (Muneta et al., 2008). Inhibition of IFN-ɣ production may enhance 
secondary viral infections such as PRRSV and swine influenza virus (Thacker et al., 1999; 
Yazawa et al., 2004). Inhibition of IL-10 may lead to over activation of macrophages and 
tissue damage because of its important anti-macrophage activity (Muneta et al., 2008). 
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Indeed, induction of IL-10 secretion by vaccination resulted in a lower influx of macrophages 
in the bronchoalveolar lymphoid tissue in vaccinated pigs compared to non-vaccinated 
animals, after experimental infection with M. hyopneumoniae (Vranckx et al., 2012). 
Helper T cells (Th) are an important component in the response to mycoplasma 
respiratory disease and are the most numerous subset in the lymphoid infiltration. Although 
less numerous, cytotoxic T-cells are also observed in lung lesions caused by M. 
hyopneumoniae (Sarradell et al., 2003). Th-1 cells are responsible for activating and 
increasing phagocytic and cytotoxic activities of macrophages (Asai et al., 1994; Messier et 
al., 1990). Therefore, the presence of T-cells and overproduction of certain cytokines such as 
IL-1 and IFN-ɣ exacerbate the host mediated tissue damage. 
Specific lung sections of pigs inoculated with M. hyopneumoniae revealed that cells 
producing IgM, IgA and IgG were present (Messier et al., 1990). In addition, particular 
increase in the level of IgG and IgA is found in tracheobronchial secretions, lungs and serum 
of naturally or experimentally infected pigs (Messier et al., 1990; Redondo et al., 2009; 
Rodriguez et al., 2004; Suter et al., 1985). IgG participates in opsonization and phagocytosis 
by alveolar macrophages, whereas IgA seems important in local immunity (Sarradell et al., 
2003).  
The induction of an immune response by M. hyopneumoniae is slow, with 
seroconversion taking at least 3-6 weeks to develop in experimentally infected pigs (Thacker 
et al., 2000b). No direct correlation has been found between the induction of serum antibodies 
and protection against M. hyopneumoniae (Djordjevic et al., 1997).  
It is suggested that an effective immunity against M. hyopneumoniae requires humoral 
and cell-mediated immune responses (Haesebrouck et al., 2004; Thacker et al., 2000a). Both 
immune responses are driven by activation of CD4+ Th cells. Differentiation of naive CD4+ 
Th cells into Th1 and Th2 cells determines whether humoral or cell-mediated immunity will 
be predominant (Stevens et al., 1988). CD4+ Th1 cells are involved in the cell-mediated 
immune response and activate B cells to produce opsonizing antibodies, such as IgG2a, 
whereas CD4+ Th2 cells favour humoral immunity and secretion of IgG1 and IgA (Okamba 
et al., 2007).  
 
Mucosal Immunity 
Mucosal surfaces cover the largest surface area in the body and almost 80% of total 
immune cells in the body are localized in the mucosa-associated lymphoid tissues (MALT) 
and at mucosal sites. Nasopharyngeal MALT contains the entire repertoire of immune cells 
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which are strategically located to orchestrate regional immune functions against airborne 
infections (Mann et al., 2009).  
Mucosal immunity is central to immune homeostasis and protection against the vast 
majority of pathogens that invade via mucosal surfaces. The particular hallmark of mucosal 
immunity remains the production and presence at the luminal mucosal surfaces of secretory 
IgA (S-IgA). The production of S-IgA consists of IgA class switching of activated B cells in 
the germinal centres of mucosal tissues and lymph nodes, and their dissemination via efferent 
lymphatics through the blood stream to mucosal tissues (Meeusen, 2011). In general, S-IgA 
has multiple roles in mucosal defense (Lamm, 1997). It promotes the entrapment of antigens 
or microorganisms in the mucus, preventing direct contact of pathogens with the mucosal 
surface, a mechanism that is known as 'immune exclusion'. Alternatively, S-IgA of the 
appropriate specificity might block or sterically hinder the microbial surface molecules that 
mediate epithelial attachment (Hutchings et al., 2004). 
The role of local IgA in M. hyopneumoniae infection is not totally clear, but some 
studies found that IgA responses are, next to cell-mediated immunity, important for protection 
(Sarradell et al., 2003; Thacker et al., 2000a). M. hyopneumoniae is primarily found on the 
mucosal surface of the trachea, bronchi, and bronchioles (Blanchard et al, 1992), and the 
primary defense of this tissue is the mucosal immune system by the production of S-IgA, 
which prevents the interaction of the pathogens with receptors on the mucosal cell surface. A 
study investigating the effect of vaccination found that vaccination induced secretion of M. 
hyopneumoniae-specific antibodies into BAL fluid, suggesting that these antibodies may be 
important in the prevention or resolution of mycoplasmal pneumonia (Thacker et al., 2000b). 
Because BAL fluid is in close contact with M. hyopneumoniae organisms attached to the cilia 
of the respiratory tract, antibodies in this compartment may be an important mechanism of 
defense against clinical disease (Thacker et al., 2000a). 
However, systemic immunisation with the currently available vaccines is not able to 
generate a full protective immunity (Meyns et al., 2006; Villarreal et al., 2011b). This partial 
protection could be due to parenteral administration of bacterins. It has been demonstrated 
that systemic stimulation of the immune system mainly results in systemic protection with 
low mucosal immune responses. Conversely, optimal stimulation of the mucosal immune 
system generates both mucosal and systemic immunity (Czerkinsky et al., 1999). The ideal 
vaccine would be mucosally administered and able to stimulate a suitable mucosal immunity, 
including specific Th response and IgA, which can prevent the adherence of pathogens to 
mucosal cell surfaces (Neutra and Kozlowski, 2006).  
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1.1.4 Lesions 
 
Gross lung lesions following M. hyopneumoniae infections consist of purple to grey 
consolidated areas that are mainly located in the apical and cardiac lobes and the cranial parts 
of diaphragmatic lobes (Thacker and Minion, 2010) (Figure 2). Lesions appear from 7 days 
after experimental infection onwards and reach a maximal size at about 4 weeks after 
infection (Kobisch et al., 1993). The affected lung parts are characterized by a meaty aspect, 
while a catarrhal exudate is often present in the airways. The bronchial and mediastinal lymph 
nodes are usually enlarged (Goodwin, 1965). 
 
 
 
Figure 2: Lung of a M. hyopneumoniae infected pig. 
 
Under field conditions, the clinical symptoms and lesions are often complicated by 
infections with other respiratory pathogens (Sibila et al., 2009). A larger portion of the lung 
may be affected, lesions can be more firm and heavy, and mucopurulent exudate can be 
expressed from the airways (Thacker and Minion, 2010). A correlation between the onset of 
clinical symptoms (coughing) and pneumonic lesions has been described (Kobisch et al., 
1993). In the latter study, macroscopic lesions and coughing were seen 1 and 2 weeks post 
infection, respectively. Seven to nine weeks after infection, lesions were recovering and the 
coughing disappeared. 
Although gross lesions are suggestive of EP, they are not pathognomonic for M. 
hyopneumoniae, as other organisms may produce similar lesions. In the presence of other 
respiratory pathogens, the lesions become more diffuse and they are sometimes difficult to 
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differentiate from those induced by other pathogens like swine influenza virus or the 
combination of Pasteurella multocida and Aujeszky’s disease virus (Done, 1991; Fuentes and 
Pijoan, 1987). The lung consolidation areas regress by 2 to 4 months post-infection (Sorensen 
et al., 1997), but the organism can remain present in the lungs at least 6 months after infection 
(Fano et al., 2005). 
 Microscopically, pulmonary tissue modifications observed in pigs in the acute phase 
of infection consist of hyperplasia of the epithelial cells and an increased perivascular and 
peribronchiolar accumulation of mononuclear cells (Kobisch and Friis, 1996). In the early 
stages of the disease, there is a loss and exfoliation of cilia, and there are small accumulations 
of neutrophils in the lumina around the airways. Electron microscopy studies showed loss of 
cilia at 6-11 weeks post-infection (Blanchard et al., 1992) and the presence of mycoplasmas 
and leukocytes in affected tissue surface (Irigoyen et al., 1998). Lymphocytes and to a lesser 
extent also macrophages form cuffs around the airways. In more chronic lesions, lymphocytic 
cuffs are more prominent and may contain lymphoid nodules (Thacker and Minion, 2010). 
Lymphoid hyperplasia itself may be related to clinical signs, because pressure from 
aggregates of lymphoid tissue may obliterate the lumen of the soft-walled bronchioles and 
cause collapse of surrounding alveoli (“cuffing” pneumonia) (Baskerville, 1972). 
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1.1.5 Control measures 
 
M. hyopneumoniae infections can be controlled by combining several factors such as 
the optimization of management practices, biosecurity measures and housing conditions, and 
the use of antibiotics and vaccination (Maes et al., 2008). The improvement of management 
practices is paramount to controlling the disease, and this is the first measure that should be 
taken once M. hyopneumoniae has been detected.  
Antimicrobials such as tetracyclines and macrolides are often used to treat respiratory 
diseases such as EP (Vicca et al., 2004). Due to the localisation of the organism on the surface 
of the respiratory tract, only antimicrobials that are able to reach high concentrations in the 
mucus and the fluids of the respiratory tract are expected to be effective in vivo. Pigs treated 
with effective antibiotics have less clinical signs and lung lesions, and a lower number of 
secondary infections (Ciprian et al., 2012; Vicca et al., 2005). Despite the success of 
medication programmes in the control of M. hyopneumoniae infections, often only partial 
protection is achieved. The results may be inconsistent since outbreaks are possible when 
treatment is stopped (Thacker and Minion, 2010). Also, preventive or strategic medication of 
pigs with antimicrobials should be minimized as much as possible to avoid development of 
antimicrobial resistance. 
Vaccination with inactivated, adjuvanted whole-cell bacterins (alone or in combination 
with antibiotics) is frequently used worldwide to control M. hyopneumoniae infections 
(Haesebrouck et al., 2004). The efficacy of vaccination has been demonstrated in many 
different studies. Although vaccination confers beneficial effects in infected pigs, these effects 
are variable between herds. The variability may result from different factors such as the 
infection level, the age of infection, complicating factors and the variability between different 
isolates of M. hyopneumoniae (Calus et al., 2007; Villarreal et al., 2011a). However, 
vaccination is still considered the most effective practice for controlling this infection 
(Mateusen et al., 2002). The major advantages of M. hyopneumoniae vaccination include 
improvement of the daily weight gain (2-8%) and the feed conversion ratio (2-5%), a shorter 
time to reach slaughter weight, reduced clinical signs, lung lesions and less treatment costs 
(Maes et al., 1998; Maes et al., 1999). 
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1.1.6 Vaccines 
 
1.1.6.1 Commercial Vaccines 
 
Vaccination with commercial bacterins has been an important tool to control infection 
by M. hyopneumoniae worldwide. Despite the beneficial effects, these bacterins provide only 
partial protection and do not prevent the colonization of M. hyopneumoniae on the epithelial 
cells (Thacker et al., 2000a). Some studies indicate that currently available commercial 
vaccines can reduce the number of organisms in the respiratory tract (Meyns et al., 2006; 
Vranckx et al., 2012), and consequently, the infection level in the animals, and by extension 
likely also in the herd (Sibila et al., 2007). Although vaccination significantly reduces clinical 
symptoms and lung lesions, only a limited reduction occurs in the transmission of M. 
hyopneumoniae (Meyns et al., 2006; Villarreal et al., 2011b). These findings reinforce the 
idea that vaccination alone is not sufficient to eliminate M. hyopneumoniae in infected pig 
herds. To achieve desirable results, vaccination should be practiced in combination with other 
management factors controlling the infection (Haesebrouck et al., 2004). 
Despite the fact that vaccination against M. hyopneumoniae is widely practiced, many 
aspects about its effect on transmission of the pathogen, effect on different strains and on the 
immunological response remain unclear and need to be further investigated. Nevertheless, 
studies suggest that mucosal antibodies and systemic immune responses are important for the 
control of this disease (Thacker et al., 2000a). The commercial vaccines induce the production 
of specific antibodies in serum, although the antibody response may differ between the 
vaccines (Thacker et al., 1998), and the seroconversion rate among animals can range from 
30% – 100% (Sibila et al., 2004). The correlation between the induction of specific antibodies 
and protection against pneumonia is unclear. Challenge experiments in pigs have shown that 
the concentrations of antibodies in serum are not correlated with protection against M. 
hyopneumoniae (Djordjevic et al., 1997). Thus, the presence and concentration of antibodies 
in serum do not appear to be the best way to evaluate protective immunity.  
Few studies have evaluated the effects of vaccination of the commercial bacterins on 
mucosal immune system and cell mediated immunity. Thacker et al. (2000a), evaluating BAL 
fluid and lymphocytes isolated from blood, indicated that a commercial vaccine induces a 
local mucosal and systemic cell mediated immune response detected by ELIspot and ELISA. 
However, the vaccination failed to induce nonspecific changes in the peripheral CD4
+ 
and 
CD8
+ 
cells, analyzed by flow cytometry. In contrast, differences between vaccinated and 
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control pigs in CD4
+ 
and CD8
+ 
 cells were detected in a study performed by Kick et al. (2011). 
This indicates that there is considerable variation between published reports and that little is 
known about the exact mechanism of protection of the commercially available M. 
hyopneumoniae vaccines. 
All commercially available M. hyopneumoniae vaccines are made from killed 
mycoplasma cultures (bacterins) but have different adjuvants. Some adjuvants are considered 
relatively mild, like aluminium salts, whereas the oil-based ones, usually in the form of 
emulsions, are more reactive and may take a longer time to be taken up, therefore giving a 
more prolonged release and stimulation (Yuki and Kiyono, 2003). The difference in adjuvant 
composition in commercial vaccines might also influence the type of induced immune 
response and the levels of protection. 
Besides this, the current commercial vaccines used to control enzootic pneumonia are 
mostly based on the J-strain, which was originally isolated from a pig herd in the UK 
(Goodwin and Whittlestone, 1963). The variable results observed in the vaccine efficacy 
under field conditions may be due, among other factors, to antigenic differences between the 
strains circulating in pig herds and the vaccine strain. 
The role of maternal immunity in protection of newborn piglets is not entirely clear 
and the potential interference with development of active immunity needs to be better 
understood. It has been demonstrated that lymphocytes that were passively transferred from 
vaccinated dams to their offspring in colostrum were able to proliferate and participate in a 
functional response to M. hyopneumoniae (Bandrick et al., 2008). Also, it has been shown that 
passive immunity induced by sow vaccination may be consistent with early vaccination to M. 
hyopneumoniae in piglets (Martelli et al., 2006). One study reported that a single dose of M. 
hyopneumoniae bacterin to pigs of approximately 1 week of age induced long-lasting 
protective immunity, with reduction in the extent of lung lesions after challenge with a 
virulent strain of M. hyopneumoniae (Reynolds et al., 2009). An early vaccination regimen 
should induce immunity around the time of weaning, when pigs from different litters are 
mixed together, and are likely to face their first infectious challenge, and when the risk of 
developing multi-factorial severe pneumonia is exacerbated (Martelli et al., 2006). Meyns et 
al. (2004) and Villarreal et al. (2011b) estimated under experimental and field conditions, 
respectively, that one infected animal will infect an average of one susceptible penmate 
during a nursery period of 6 weeks. These results emphasize the importance of the 
implementation of control strategies from an early age onwards. 
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Different strategies of vaccination have been adopted depending on the needs of a 
particular herd and variables such as the production system, type of herd, infection pattern and 
preferences of the pig producer. The decision to vaccinate or not depends on the economic 
feasibility in the farm and the profits that the vaccination will bring in relation to the 
economic losses caused by the disease (Maes et al., 2008).  
In table 1, a description of some commercially available vaccines against M. 
hyopneumoniae licensed in Europe is given. Commercial names, antigen and adjuvant 
constitution are presented, as well as the indications of administration. 
 
Table 1: Commercially available M. hyopneumoniae bacterins licensed in Europe (2013) 
*No information available 
 
Vaccine Strain Adjuvant 
Route of 
administration 
Age of 
administration 
Boosts 
needed 
 
HYORESP 
(Merial) 
NI* 
Aluminium 
hydroxide 
IM >5 days 
3-4 
weeks 
 
INGELVAC 
MYCOFLEX 
(Boehringer 
Ingelheim) 
J strain isolate  
B-3745 
Impran (water-
in-oil adjuvant  
emulsion) 
IM >21 days - 
 
M+Pac 
(Intervet Int.) 
NI* 
Aluminium 
hydroxide 
IM >7 days 
3-4 
weeks 
 
MYPRAVAC 
SUIS (Hipra Lab) 
J strain 
Levamisole and 
carbomer 
IM 7-10 days 3 weeks 
 
PORCILIS M. 
HYO (Intervet) 
Strain 11 
dl--tocopherol 
acetate 
IM 7 days 3 weeks 
 
STELLAMUNE 
MYCOPLASMA 
(Eli Lilly) 
NL 1042 
Mineral oil 
and lecithin 
IM 7 days 
2-4 
weeks 
 
STELLAMUNE 
ONCE (Eli Lilly) 
NL 1042 
Amphigen Base, 
and Drakeol 5 
(mineral oil) 
IM 7 days - 
 
SUVAXYN 
M.HYO 
 (Pfizer A.H.) 
P-5722-3 Carbopol IM 7 days 2 weeks 
 
SUVAXYN MH-
ONE (Pfizer A.H.) P-5722-3 
Carbopol and 
squalane IM 7 days - 
 
SUVAXYN 
M.HYO 
PARASUIS 
(Pfizer A.H.) 
P-5722-3 Carbopol IM 7 days 2 weeks 
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1.1.6.2 Development of new generation vaccines against M. hyopneumoniae 
 
In recent years, there has been a remarkable expansion of new approaches to identify 
relevant antigenic components for use in vaccines, and these new techniques are beginning to 
be applied in the development of veterinary vaccines (Movahedi and Hampson, 2008). 
Progresses in microbiology, molecular biology, immunology and bioinformatics have led to a 
more rational approach in vaccine development (Haesebrouck et al., 2004). For many 
diseases, this new approach can be an alternative to replace the traditional method of vaccine 
preparation, which follows the principles established by Pasteur (Rappuoli, 2001).  
With recombinant DNA technology, the "second generation" vaccines emerged based 
on the use of recombinant proteins. More recently, the availability of complete genome 
sequences have led to a new approach in vaccine development (Scarselli et al., 2005), called 
reverse vaccinology (Rappuoli, 2001). The reverse vaccinology approach starts from the 
genomic sequence and, by computer analysis, predicts those antigens that are most likely to 
be vaccine candidates. The approach can, therefore, be very simple, and poses the question of 
whether any of the potential antigen candidates can provide protective immunity (Rappuoli, 
2001). This has led to a "third generation" of vaccines (Movahedi and Hampson, 2008).  
The combination of in silico analysis of whole genome sequences and recombinant 
DNA technology has several advances in the development of third generation vaccines 
(Movahedi and Hampson, 2008). Through computational analysis, virtually all proteins that 
the pathogen can express both in vivo and in vitro can be selected, without prior knowledge of 
their abundance, immunogenicity or expression during infection (Movahedi and Hampson, 
2008). After selecting a group of genes of the genome, the next steps include: cloning and 
expression of selected genes, purification of recombinant proteins to identify potential 
candidates for protection (Grandi, 2001). Advantages of recombinant subunit vaccines are 
numerous. First of all, the pathogen can be entirely excluded from the production of the 
vaccine, which eliminates the risks associated with contamination by toxic compounds, and 
reversion to virulence. Besides, the possibility of optimizing the presentation forms of these 
antigens (Liljeqvist and Stahl, 1999). 
However, one of the major disadvantages is that the reverse vaccinology can be applied 
only for the discovery of protein antigens and not for other antigens like lipopolysaccharides 
and glycolipids, which are important components of many successful vaccines. In addition, 
the feasibility of the approach relies heavily on the availability of a high-throughput system to 
screen protective immunity. Unfortunately, the limited knowledge of vaccine immunology 
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makes it difficult to find correlations with protection and, therefore, screening for protective 
immunity is the rate-limiting step of reverse vaccinology (Rappuoli, 2001; Serruto and 
Rappuoli, 2006). Besides, the necessity of having the publication of the complete genome 
sequence of many bacteria, parasites and viruses. 
The genome sequencing of four M. hyopneumoniae strains (Liu et al., 2011; Minion et 
al., 2004; Vasconcelos et al., 2005), has allowed the rational choice of sequences that encode 
proteins that might be used for the development of a protective vaccine and for use in 
diagnostic tests of EP. The small genome of this agent, as well as, the limited number of 
secreted or surface proteins favours the use of reverse vaccinology.  
The technology of recombinant DNA associated with the approach of the reverse 
vaccinology have provided valuable tools for the production of M. hyopneumoniae 
recombinant proteins in heterologous systems. The recombinant subunit vaccines are based on 
fractions of the organism and are produced using heterologous protein expression systems.  
The heterologous recombinant proteins can be produced in both eukaryotic and 
prokaryotic organisms and, once expressed, can be readily purified and administered to 
animals in high concentrations (Clark and Cassidy-Hanley, 2005). E. coli is the most 
attractive system for production of recombinant proteins (Baneyx, 1999). However, despite 
the fact that genetic characteristics of E. coli are well known, not all genes can be efficiently 
expressed in this microorganism. An example is the expression of genes from M. 
hyopneumoniae containing codons TGA. TGA encodes the amino acid tryptophan in 
Mycoplasma, while it is a stop codon in other organisms. This feature has hindered the 
expression of these genes in E. coli. Mutations capable of replacing TGA by TGG have been 
the strategy used to circumvent this problem. Simionatto et al. (2009) described the 
optimization of a PCR protocol for site directed mutation in codon TGA genes from M. 
hyopneumoniae, obtaining satisfactory results in the expression of these genes in E. coli. 
Constant effort is being directed towards the investigation of new vaccines that may 
offer a better protection against M. hyopneumoniae infections. Several studies have evaluated 
recombinant proteins of M. hyopneumoniae, in various forms of administration and 
formulations. Some of them were evaluated individually (Galli et al., 2012; Simionatto et al., 
2012), others were associated with attenuated bacterial or viral vectors (Chen et al., 2006a; 
Chen et al., 2006b; Chen et al., 2001; Fagan et al., 2001; Okamba et al., 2010; Okamba et al., 
2007; Shimoji et al., 2003; Zou et al., 2011), fused to mucosal adjuvants (Conceição et al., 
2006), and also evaluated as a pool of antigens (Chen et al., 2008). Most of these recombinant 
proteins were evaluated only in mice. Only a few of them were tested in challenge 
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experiments in pigs. Differences in the immunity induced by these antigens were observed, 
which might be due to differences in the vaccine constructs, the route of immunization, the 
correct folding and/or other post-translational modification that may contribute to the ability 
to generate antibodies by the antigens (Pinto et al., 2007a). These evaluations suggest that 
these new vaccine approaches may represent promising strategies, and may be economically 
feasible to control EP. Table 2 summarizes the antigens, adjuvants, vectors and routes of 
immunization used in the studies on experimental M. hyopneumoniae vaccines so far. 
 
 
Table 2: Overview of experimental vaccines against M. hyopneumoniae 
* 34 previously uncharacterized recombinant proteins of M. hyopneumoniae were evaluated in this study. 
** Intramuscularly 
*** Subcutaneously 
**** Intranasal  
Antigen 
Kind of 
vaccine 
Vector/Adjuvant Species Route 
Challenge 
infection 
Reference 
P97 
Recombinant 
Subunit 
Freund’s pig 
IM** 
 
yes 
King et al., 
1997 
NrdF (R2) 
Recombinant 
Vector 
Salmonella Typhimurium  
aroA SL3261 
mice 
Oral 
 
no 
Fagan et al., 
1997 
P97 (R1) 
Recombinant 
Vector 
Pseudomonas exotoxin A 
mice 
and 
 pig 
SC*** 
 and IM 
no 
Chen et al., 
2001 
NrdF (R2) 
Recombinant 
Vector 
Salmonella Typhimurium  
aroA SL3261 
pig 
Oral 
 
yes 
Fagan et al., 
2001 
P42 
 
DNA pcDNA3 mice IM no 
Chen et al., 
2003 
P97 (R1R2) 
Recombinant 
Vector 
Erysipelothrix 
rhusiopathiae  
YS-1 
mice 
and  
pig 
SC and  
IN**** 
 
no 
Shimoji et 
al., 2003 
P97 (R1) 
Recombinant 
Vector 
Salmonella Typhimurium  
aroA CS332 
mice 
Oral 
 
no 
Chen et al., 
2006a 
NrdF (R2) 
Recombinant 
Vector 
Salmonella Typhimurium  
aroA CS332 
mice 
Oral 
 
no 
Chen et al., 
2006b 
P97 (R1) 
Recombinant 
Subunit 
LTB mice 
IM and  
IN 
no 
Conceição et 
al., 2006 
P97 (R1) 
Recombinant 
Vector 
Adenovirus mice 
IM and  
IN 
no 
Okamba et 
al., 2007 
P97 (R1R2) 
Recombinant 
Vector 
Erysipelothrix 
rhusiopathiae 
 Koganei 
pig 
Oral 
 
yes 
Ogawa et 
al., 2009 
P97 (R1) 
Recombinant 
Vector 
Adenovirus pig 
IN 
 
yes 
Okamba et 
al., 2010 
P36 
Recombinant 
Vector 
Actinobacillus 
pleuropneumoniae 
SLW36 
mice 
IM 
 
no 
Zou et al., 
2011 
34* 
Recombinant 
Subunit 
Aluminun mice 
IM 
 
no 
Simionatto 
et al., 2012 
P37, P42,  
P46, P95 
Recombinant 
Subunit  and 
DNA 
Aluminun and 
 pcDNA3 
mice 
IM 
 
no 
Galli et al., 
2012 
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The P97 protein, which was identified as an important adhesin of M. hyopneumoniae 
(Zhang et al., 1995) has been the most studied and best defined potential protective antigen. It 
has been evaluated in several studies using different vaccine formulations. King et al. (1997) 
reported that a subunit vaccine based on recombinant adhesin P97 did not induce significant 
protection in challenged pigs. However, when the C-terminal region of P97 (R1) was fused to 
Pseudomonas toxin A, immunized mice and pigs produced specific immune responses against 
R1 (Chen et al., 2001). Oral vaccination with recombinant E. rhusiopathiae strains expressing 
the P97 protein reduced the severity of pneumonic lung lesions caused by M. hyopneumoniae 
infection, showing that E. rhusiopathiae may be a promising vaccine vector for delivering 
foreign antigens to the immune systems of pigs (Ogawa et al., 2009).  
Apart from the antigen in the vaccine, also the adjuvant and the route of immunization 
play a role in protection. Mucosal adjuvants and intranasal vaccine delivery have received 
special attention as alternatives that may increase the mucosal immunity. Conceição et al. 
(2006) have reported that a recombinant subunit vaccine containing the R1 subunit of P97 
fused to the B subunit of thermolabile enterotoxin of E. coli (rLTBR1), a parenteral and 
mucosal adjuvant, induced systemic and mucosal antibodies against R1 in mice. Shimoji et al. 
(2003) reported that a YS-19 attenuated strain of Erysipelothrix rhusiopathiae expressing the 
R1 region of P97 was able to reduce lung lesions in intranasally (IN) immunized pigs when 
they were challenged. However, there was no humoral or cell-mediated immune response. 
Further, Okamba et al. (2007) showed that mice immunized IN with defective adenovirus 
expressing the C-terminal region of P97 (rAdP97c) induced a systemic Th1/Th2 immune 
response and local immunity. This same construct was evaluated in pigs in comparison with a 
commercial vaccine. rAdP97c significantly reduced the severity of the inflammatory response 
and the amount of M. hyopneumoniae in the respiratory tract. Also the average daily weight 
gain was slightly improved. However, the commercial vaccine was more effective in inducing 
protective immunity (Okamba et al., 2010). These results suggest that the kind of immunity 
induced by this antigen may be influenced by differences in the vaccine construct, the route of 
immunization, and the adjuvant or vector used. 
Mice immunized orally with Salmonella Typhimurium aroA CS332 harboring the R1 
region of P97 (Chen et al., 2006a) and the R2 subunit of ribonucleotide reductase (NrdF) of 
M. hyopneumoniae (Chen et al., 2006b) showed a Th1-based immune response, but no 
humoral or mucosal immune responses. However, when the NrdF R2 subunit was expressed 
in Salmonella Typhimurium aroASL3261, a mucosal immune response was observed in mice 
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(Fagan et al., 1997). When used for immunizing pigs, this antigen was able to reduce lung 
lesions caused by an experimental M. hyopneumoniae infection (Fagan et al., 2001).  
Apart from recombinant subunit vaccines that have been evaluated in mice and pigs, 
immune responses to DNA vaccines in mice have also been investigated. DNA vaccines 
based on heat shock protein P42 induced both Th1 and Th2 immune responses in mice. In 
addition, antiserum from the immunized animals was found to inhibit the growth of M. 
hyopneumoniae in vitro (Chen et al., 2003). Similar results were described using a DNA 
vaccine with the antigen P46. Both Th1 and Th2 immune responses were obtained in mice, 
with an increase in the IFN-γ level (Galli et al., 2012). Thus, DNA vaccines might represent a 
promising strategy for control of EP. 
Despite the immunizing properties of the recombinant antigens and DNA vaccines 
tested so far, none of them was able to induce a protection as good as the commercial 
vaccines. Multivalent formulations could be another alternative in offering better protection 
against M. hyopneumoniae (Chen et al., 2008). Five recombinant antigens of M. 
hyopneumoniae (P97, P97R1, NrdF, P36, and P46) were evaluated as DNA and protein 
vaccines. The analysis of mice immunized with the cocktail of antigens administered as DNA 
vaccine revealed that only P97 and P36 induced IgG in the serum. Intramuscular 
immunization with a cocktail of antigens (P97, P97R1, NrdF, P36, and P46) as a DNA 
vaccine induced a Th1 immune response, while antibody responses appeared to be antigen 
dependent. Subcutaneous immunization with the same cocktail administered as a recombinant 
subunit vaccine induced humoral and Th1 immune responses. When a combination of DNA 
and subunit vaccine was used, both humoral and Th1 responses were obtained. In addition, 
P97 was not recognized by serum antibodies from mice immunized with a commercial 
bacterin, which may be an indication of the lack of expression of this antigen in inactivated 
whole-cell vaccines (Chen et al., 2008). 
The identification and characterization of immunogenic M. hyopneumoniae proteins is 
an important step towards the development of improved vaccines. Despite the difficulties due 
to the unusual codon of mycoplasmas (Razin et al., 1998), Simionatto et al. (2009; 2010) have 
previously reported the cloning and expression of a high number of M. hyopneumoniae 
recombinant proteins in E. coli. Antigenic and immunogenic properties of these proteins were 
analysed. Some of them were evaluated in mice and showed to be potential as vaccine 
candidates against M. hyopneumoniae. Although the immune response of mice cannot be 
extrapolated to other species, the results warrant further investigation with promising proteins 
as subunit vaccines in challenge experiments in pigs (Simionatto et al., 2012).  
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Most of these experimental vaccines must be evaluated in pigs under both 
experimental and field conditions. To date, few formulations have been assessed in M. 
hyopneumoniae challenge experiments in pigs (Fagan et al., 2001; Ogawa et al., 2009; 
Okamba et al., 2010), and these conferred only partial protection with some reduction of 
pulmonary lesions. 
 
1.1.6.3 Mucosal Adjuvants: Immunomodulation by Bacterial Enterotoxins 
 
Taking into consideration the above discussion, it is clear that we require a safe and 
effective vaccine against M. hyopneumoniae. Considering that genetically engineered 
vaccines composed of a single recombinant antigen, particularly subunit vaccines are poorly 
immunogenic, it is important to increase their immunogenicity by combining them with 
appropriate adjuvants (Soria-Guerra et al., 2011). 
Currently used adjuvants such as aluminum hydroxide or phosphate have a 
demonstrated safety profile of many decades and their role in the implementation of 
successful vaccine programmes is impressive. However, these adjuvants have been associated 
with severe local reactions, such as erythema, subcutaneous nodules and contact 
hypersensitivity (Baylor et al., 2002). Oil emulsions of various compositions are also widely 
used as adjuvant in M. hyopneumoniae vaccines. They have been considered as potent 
adjuvants even though they have a tendency to induce granulomas at the injection sites 
(Aucouturier et al., 2001). 
Inducing mucosal immunity with toxin-derived immune adjuvants has received a lot 
of attention, especially for vaccine development for bacterial pathogens. As M. 
hyopneumoniae infection starts in the respiratory tract, the ideal vaccine would be mucosally 
administered and able to stimulate a suitable mucosal immunity, including specific  T helper 
(Th) response and immunoglobuline A (IgA), which can prevent the adherence of pathogens 
to mucosal cell surfaces (Neutra and Kozlowski, 2006).  
One strategy has been to employ bacterial enterotoxins such as cholera toxin (CT) 
from Vibrio cholera or the related subunit B of heat-labile enterotoxin of Escherichia coli 
(LTB), a non-toxic subunit. These have been shown to be highly immunogenic, demonstrate 
potent immune-modulatory activity with a range of antigens either fused or co-administered 
to them, in different animal models, enhance immunogenicity as well as to confer protective 
efficacy (Conceição et al., 2006; da Hora et al., 2011; Grassmann et al., 2012; Qiao et al., 
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2009; Zhou et al., 2009). They are considered as potent mucosal and parenteral adjuvants 
(Cox et al., 2006; da Hora et al., 2011; Simmons et al., 2001), enhancing both mucosal IgA as 
well as systemic antibody responses. 
In developing veterinary mucosal vaccines and vaccination strategies, mucosal 
adjuvants are one of the key players for inducing protective immune responses. The biological 
effects of CT and LTB are mediated by the binding and internalization of the molecules into 
mammalian cells. The principle receptor for both is GM1-ganglioside, a glycosphingolipid 
found ubiquitously on the surface of all cells, including enterocytes, dendritic cells, 
macrophages, B and T lymphocytes (Cox et al., 2006). 
Although the mechanisms by which the enterotoxin-based adjuvants exert 
immunomodulating effects are not well characterized, enhancement of inflammatory cytokine 
and chemokine production and transient recruitment of immune effectors cells to the site of 
immunization are likely involved (Ryan et al., 2000). LTB is also known to influence the 
dendritic cell maturation (Petrovska et al., 2003), antigen presentation and T-cell activation 
and promote the induction of antigen-specific cytotoxic T lymphocyte responses in mouse 
models (Fu et al., 2009). The use of LTB as an adjuvant has resulted in balanced cytokine 
response, involving the production of both Th1 and Th2 cytokines (Fromantin et al., 2001). 
The competence of LTB to modulate or improve vaccine-induced immune responses 
appears to depend to some extent on the antigen-LTB combination (there are difference in 
response for the B subunit whether it is used as a mixture or coupled to the antigen), the 
vaccination route and the dose (da Hora et al., 2011). The route of administration appears to 
be a critical factor influencing the immune-enhancing activities of LTB. Although LTB has 
demonstrated potent mucosal adjuvanticity when administered intranasally or orally (Fingerut 
et al., 2006; Richards et al., 2001; Yamanaka et al., 2006), it also stimulated a strong systemic 
and secretory response when administered parenterally (Fischer et al., 2010). 
Bacterial enterotoxins as LTB have provided important insights into immunological 
mechanisms associated with mucosal adjuvant activity and significant practical benefits may 
follow in the form of new mucosal vaccines against M. hyopneumoniae. Conceição et al. 
(2006) have shown that immunization of mice with pure recombinant R1 of P97 adhesin did 
not induce specific systemic and mucosal antibodies to R1. In contrast, immunization with the 
R1 region fused to the B subunit of the heat-labile enterotoxin B subunit of E. coli (rLTBR1) 
produced high levels of specific antibody and cellular responses. However, the efficacy of this 
vaccine has not been tested in swine. 
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Despite the advantage of mucosal vaccinations for the prevention of M. 
hyopneumoniae, the number of experimental vaccines evaluating this route of immunization 
is still very limited. This is mainly due to important difficulties that are encountered by using 
the mucosal route such as: 
(1) the antigen should pass the mucosal barrier in sufficient amount,  
(2) mucosal tolerance mechanisms should be overcome,  
(3) protective immune mechanisms should be activated and  
(4) minimal/or no influence on mucosal functionality should occur. 
Mucosal adjuvants are crucial in reaching these goals (Cox et al., 2006). However, E. 
coli heat-labile toxin (LT) has also been shown to have negative side effects in humans, as 
both native and mutant LT (mLT) used as adjuvants were recently associated with the 
development of facial nerve paralysis following intranasal delivery in humans (Lewis et al., 
2009). It is, therefore, evident that these toxin adjuvants exhibit safety concerns that will 
likely prevent their use in nasally delivered vaccines for humans. Moreover, the B subunits of 
CT (CTB) and LT (LTB), which are not toxic, have been shown to promote tolerance to 
heterologous antigens. CTB has been the most studied, especially as conjugates with antigens. 
It has been tested in clinical assays for possible prevention of auto-immune and allergic 
diseases. Most of the studies of CTB conjugate with antigens showed to induce protective 
regulatory T cells in animal models of auto-immune or inflammatory diseases (Basset et al., 
2010). However, the adjuvant activity of the B subunit has been a source of controversy and 
the many questions about the effects of these adjuvants remains confusing.  
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2. Aims of the study 
 
Mycoplasma hyopneumoniae is the primary pathogen of enzootic pneumonia, a 
chronic respiratory disease that is widespread and causes major economic losses to the swine 
industry worldwide. Control measures include the optimization of management and housing 
conditions, the use of strategic medication and/or vaccination. However, the current control 
measures are beneficial from an economic point of view, but they do not provide a sustainable 
control of the disease. They cannot prevent colonization of M. hyopneumoniae in the 
respiratory tract, and do not significantly reduce the transmission of the pathogen. Also little 
is known about the exact mechanisms of the partial protection they induce.  
The general aims of this thesis were, therefore, to assess the mode of the action of an 
existing commercial vaccine on the one hand and to develop and evaluate new recombinant 
vaccines against M. hyopneumoniae on the other hand, looking for more effective strategies 
for disease control. For development of the recombinant vaccines, two types of antigens were 
considered. One vaccine was based on proteins known to play a role in the adhesion and that 
were able to induce a partial protection against M. hyopneumoniae infection when evaluated 
individually. The other antigens were a group of transmembrane proteins (not previously 
characterized). The identification of these novel antigens might contribute to the development 
of improved vaccines. 
The specific objectives were: 
1. To analyze the systemic as well as the local mucosal immune response induced by 
intramuscular administration of a commercial M. hyopneumoniae vaccine in pigs. 
2. To produce a recombinant chimeric protein composed of the P97R1, P42 and NrdF 
antigens of M. hyopneumoniae fused to LTB and to evaluate the capacity of this 
chimeric protein to induce a specific immune response in mice and pigs. 
3. To identify, clone and characterize transmembrane proteins from M. hyopneumoniae 
which may be useful in vaccination against enzootic pneumonia. 
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Abstract 
The immune response induced by intramuscular administration of a commercial inactivated 
Mycoplasma hyopneumonie whole-cell vaccine (Suvaxyn®MH One) was investigated in 
conventional M. hyopneumoniae-free pigs. The animals were assigned randomly to two 
groups: non-vaccinated and vaccinated. Pigs in the vaccinated group were injected 
intramuscularly with the vaccine at 7 days of age, whereas non-vaccinated pigs received 
physiological saline solution (PBS). Pigs were euthanized and necropsied at 30, 36 and 58 
days of age. Blood, bronchoalveolar lavage (BAL) fluid, spleen, lung and bronchial lymph 
nodes (BLN) were collected. Serum and BAL fluid were tested for the presence of antibodies 
by ELISA. Monomorphonuclear cells from the peripheral blood and tissues were isolated to 
quantify the T cell subsets by flow cytometry, and cytokine production by ELIspot and 
ELISA. Antibodies against M. hyopneumoniae were detected in serum of most vaccinated 
pigs at 30 days of age. M. hyopneumoniae specific IgG, IgM and IgA were detected in BAL 
fluid from vaccinated animals, but not from control animals. Significantly higher numbers of 
IL-12 secreting cells were observed in the lung at day 58 in the vaccinated than in the non-
vaccinated group (p<0.05). The number of IL-10 secreting cells from BLN was also higher in 
the vaccinated group at day 58 (p<0.05). After restimulation in vitro, lymphocytes from BLN 
and lungs secreted significantly higher levels of IL-12 in the vaccinated group at day 58. 
These results show that the vaccine induced both systemic and mucosal cellular and humoral 
immune responses. 
Keywords: Mycoplasma hyopneumoniae; enzootic pneumonia; vaccine; immune response 
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Introduction 
Mycoplasma hyopneumoniae (M. hyopneumoniae) is the primary pathogen of enzootic 
pneumonia (EP). The disease occurs worldwide and causes important economic losses to the 
pig industry (Maes et al., 2008). Optimization of housing and management procedures 
combined with vaccination are the most effective tools to control EP (Lin et al., 2003; Maes et 
al., 2008). The currently used vaccines consist of adjuvanted, inactivated, whole-cell 
preparations and have been proven  to be effective in reducing the clinical symptoms and lung 
lesions, and in decreasing performance losses associated with M. hyopneumoniae infections 
(Maes et al., 2008). They are very frequently used worldwide in commercial pig herds. 
The commercial vaccines induce specific antibodies in serum, although no direct 
correlation has been found between the induction of antibodies and protection against M. 
hyopneumoniae (Djordjevic et al., 1997). Some studies suggest that mucosal antibodies and 
cellular immune responses might be important for the control of this disease (Thacker et al., 
2000).  
Only in few studies the effects of vaccination on mucosal and cell mediated immunity 
have been evaluated. Studies on bronchoalveolar lavage (BAL) fluid and lymphocytes 
isolated from blood evaluated by ELIspot and ELISA showed that a commercial inactivated 
vaccine induces mucosal and systemic cell mediated immune response. However, the 
vaccination failed to induce changes in the peripheral CD4
+ 
and CD8
+ 
cells population 
(Thacker et al., 2000). In contrast, differences between vaccinated and control pigs in the 
percentage of these cell populations, were detected in a study performed by Kick et al. (2011). 
The considerable variations between published reports demonstrate that the exact mechanism 
of protection induced by inactivated M. hyopneumoniae vaccines is not known. 
The aim of this study was, therefore, to analyze the systemic as well as mucosal 
immune responses induced by intramuscular vaccination of pigs with a commercial M. 
hyopneumoniae inactivated whole-cell vaccine that had previously been shown to be effective 
in reducing disease signs and lung lesions associated with M. hyopneumoniae infection (Vraa-
Andersen and Christensen, 1993). 
 
Materials and methods  
Experimental design  
The study was performed after approval by the Ethical Committee for Animal 
Experiments of the Faculty of Veterinary Medicine, Ghent University (approval number 
EC2011/038). Thirty-three cross-bred healthy piglets free of M. hyopneumoniae and PRRSV 
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were used in this study. All animals were obtained from a herd that has been free of M. 
hyopneumoniae and PRRSV for more than 15 years based on repeated serological testing and 
absence of clinical symptoms and pneumonia lesions. At one week of age, blood for serology 
was collected from all animals. Thereafter, the piglets were randomly allocated to two 
different groups. At 7 days of age, 17 pigs of the vaccinated group were intramuscularly 
injected with 2 ml of the commercial M. hyopneumoniae vaccine Suvaxyn®MH One, Pfizer 
Animal Health, and 16 pigs of the control group were intramuscularly injected with 2 ml of 
phosphate buffered saline (PBS). The piglets were weaned at 24 days of age, transported to 
the Faculty of Veterinary Medicine, Ghent University, where they were necropsied at 30, 36 
and 58 days of age. All piglets were euthanized by deep anesthesia with 0.3 ml/kg of a 
mixture of Xylazin (Xyl-M 2%®, VMD, Arendonk, Belgium) and Zolazepam and Tiletamine 
(Zoletil® 100, Virbac, Louvain la Neuve, Belgium), followed by exsanguination. At 
necropsy, lungs were macroscopically examined for the presence of lesions and blood and 
tissue samples from the spleen, the bronchial lymph nodes (BLN) and lungs were taken from 
all pigs. The lungs were removed and bronchoalveolar lavage (BAL) fluid was collected from 
the right lung. Blood was collected and part of it was used for serology. The other part was 
mixed with heparin (1:1000) and used for isolation of peripheral blood monomorphonuclear 
cells (PBMCs).  
Nested and quantitative PCR (qPCR) for detection of M. hyopneumoniae DNA 
 DNA was extracted from the BAL with the QIAGEN protocol (QIAGEN, DNeasy 
Blood & Tissue kit, Belgium). For detection of M. hyopneumoniae DNA, both a nested and 
qPCR were performed as described previously (Marois et al., 2010; Stark et al., 1998), in 
order to avoid false negative results. 
Isolation of monomorphonuclear cells from blood and tissues 
PBMCs were isolated by density gradient centrifugation on Lymphoprep™ (Axis-
Shield, Oslo, Norway). After lysis of erythrocytes in ammonium chloride (0.83%) and 
subsequent centrifugation, the pelleted cells were washed, resuspended in PBS with 1 mM of 
EDTA and counted. 
After euthanasia, monomorphonuclear cells were isolated from the lungs, the BLN and 
the spleen. The monomorphonuclear cells were isolated by tearing the tissue apart, followed 
by lysis of erythrocytes with 0.15 M ammonium chloride. After centrifugation, the pelleted 
cells were washed, resuspended in leukocyte medium and counted (Van den Broeck et al., 
1999). 
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Detection of M. hyopneumoniae-specific antibodies  
Serum collected from the pigs at the day of vaccination and at necropsy was analysed 
for the presence of antibodies against M. hyopneumoniae using a blocking ELISA (IDEIA™ 
Mycoplasma hyopneumoniae EIA kit, Oxoid Limited, Hampshire, UK).  
To determine the isotype of M. hyopneumoniae-specific antibodies in serum, 
peroxidase labeled goat anti-porcine IgA, IgG and IgM polyclonal antibodies (Bethyl 
Laboratories, Texas, TX, USA) and M. hyopneumoniae antigen coated microtitre plates from 
the IDEXX Mhyo ELISA (IDEXX, Hoofddorp, The Netherlands) commercial kit were used. 
Previous experiments have shown that no reaction can be detected in BAL fluid using 
plates from the IDEXX kit which was developed for detection of antibodies in serum, so 
plates were coated with Tween®20 extracted M. hyopneumoniae antigens (Bereiter et al., 
1990). BAL fluid samples were assayed for IgG, IgM and IgA antibodies against M. 
hyopneumoniae using peroxidase labeled goat anti-porcine IgA, IgG and IgM polyclonal 
antibodies (Bethyl Laboratories). The BAL fluid was tested undiluted. OD at 450 nm was 
measured and the mean OD value of the serum from the non-vaccinated animals plus two 
times the standard deviation was used as cut-off value to determine the number of positive 
animals in the vaccinated group for each immunoglobulin. Values equal to or higher than the 
cut-off were considered as positive. 
Determination of T cell populations in different tissues  
Flow cytometry was used to quantify the T-cell subset populations (CD3
+
CD4
+
, 
CD3
+
CD8
+
, CD3
+
CD4
+
CD8
+
 and CD3
+
CD4
-
CD8
-
) from the PBMCs and 
monomorphonuclear cells from spleen, the BLN and lungs. Monomorphonuclear cells (1 × 
10
6
 cells) were incubated for 20 min on ice with monoclonal antibodies against CD3 (PTT3, 
IgG1) (Yang et al., 1996), CD4 (74-12-4, IgG2b) (Percovitz et al., 1984) and CD8 (11/295/33, 
IgG2a) (Saalmuller et al., 1994) (Becton Dickinson, Erembodegem, Belgium). After the wash 
steps, the cells were incubated with the appropriate isotype-specific FITC rat anti-mouse IgG1 
(BD Pharmingen), AlexaFluor®647 goat anti-mouse IgG2a and R-phycoerythrin goat anti-
mouse IgG2b (Invitrogen). Mouse IgG1, IgG2 and IgG2b were used as isotype controls. After 
each incubation step, cells were washed twice with PBS. Finally, the cells were diluted in 400 
l and analyzed using a FACSCanto flow cytometer (Becton Dickinson Immunocytometry 
Systems, Erembodegem, Belgium) equipped with two lasers, a 488 nm solid state laser and a 
633 nm HeNe laser, and FACSDiva software. For all samples, at least 10,000 cells were 
counted. All data were corrected for autofluorescence as well as for unspecific bindings using 
isotype-matched negative controls. 
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Enumeration of cytokine secreting cells 
The numbers of IFN-ɣ, IL-10 and IL-12 secreting cells in PBMCs and tissue 
monomorphonuclear cells were determined by use of an ELIspot assay. Ninety-six well 
microtitre plates were coated with monoclonal antibodies against porcine IFN-ɣ (Swine IFN-ɣ 
Antibody Pair, Invitrogen, Merelbeke, Belgium), IL-10 (IL-10 Swine Antibody Pair, 
Invitrogen) and porcine IL12/IL23 p40 (Porcine IL-12/IL-23 p40 DuoSet, R&D Systems, 
MN, USA). After incubating the plates overnight at 4 °C (IFN-ɣ, IL-10) or at room 
temperature (IL-12), they were washed with PBS and blocked with PBS + 1% bovine serum 
albumin (IFN-ɣ) or RPMI + 10% fetal calf serum (IL-10 and IL-12) for 1 h at 37 °C (IFN-ɣ, 
IL-10) or at room temperature (IL-12), followed by a second wash step. Monomorphonuclear 
cells (5 x 10
4
/well for IFN-ɣ, IL-12 and 2 X 104/well for IL-10) in leukocyte medium alone 
(no stimulation) or with M. hyopneumoniae antigen (10 µg/ml) were added to the wells, and 
plates were incubated for 20 h at 37 °C in 5% CO2. The plates were washed and 
subsequently, incubated for 1 h at 37 °C with detection antibody diluted in assay buffer (PBS 
+ 0.5% BSA + 0.1% Tween®20 for IL-10 and IFN-ɣ and PBS + 1% BSA for IL-12). After 3 
washes streptavidin-HRP was added. After 1 h incubation at 37 °C, the plates were washed 
and the spots were developed with insoluble TMB (Sigma, Bornem, Belgium). The plates 
were scanned and the spots were counted using an Immunospot ELIspot reader (AID GmbH, 
Strassberg, Germany). Results were presented as the mean of the number of antibody 
secreting cells stimulated minus no stimulated per 10
5 
monomorphonuclear cells. 
Secretion of IFN-ɣ, IL-10, IL-12 and TGF-β in lymphocyte cultures 
Lymphocytes collected from the PBMCs, spleen, BLN and lung were seeded in 24-
well microtitre plates at a concentration of 10
6
 cells/ml in leukocyte medium (no stimulation), 
leukocyte medium with M. hyopneumoniae antigen (10 µg/ml) or leukocyte medium with 
phytohaemagglutinin (20 µg/ml) at 37 °C. Supernatant was collected after 72 h. The quantity 
of IFN-ɣ, IL-10 and IL-12 in the supernatant was measured using commercially available kits 
(Swine IFN-ɣ Antibody Pair, Invitrogen; IL-10 Swine Antibody Pair, Invitrogen and porcine 
IL-12/IL-23 p40 DuoSet, R&D Systems). For TGF-β, the TGF-β1 multispecies (TGF-β1 
Multispecies Antibody Pair, Invitrogen) was used. Samples were processed according to the 
manufacturer’s recommendations. The optical density (OD) at 450 nm was measured and the 
cytokine levels were quantified by the use of a standard curve. 
Detection of cytokines in BAL fluid 
Porcine IFN-ɣ (Swine IFN-ɣ Antibody Pair, Invitrogen), TNF-α (TNFα Swine 
Antibody Pair, Invitrogen), IL-1β (Porcine IL-1 beta/IL-1F2 DuoSet, R&D Systems) and IL-6 
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(Porcine IL-6 DuoSet, R&D Systems) were measured in BAL fluid using commercially 
available immunoassay. Samples were processed according to the manufacturer’s 
recommendations. The BAL fluid was tested undiluted. The samples reactions were measured 
using OD at 450 nm and quantified by the use of a standard curve. 
Statistical analyses 
Descriptive statistics were performed to check the normality of the variables (T cell 
populations, cytokines and serum immunoglobulins). In case data did not fulfil the criteria of 
normality, a non-parametric Kruskal-Wallis ANOVA was used. Results were considered 
significantly different at p<0.05 (two-sided test). All analyses were performed with SPSS 19.0 
for Windows (SPSS inc. Illinois, USA). 
 
Results 
Macroscopic lung lesions, nested and qPCR for detection of M. hyopneumoniae DNA 
In none of the pigs lung lesions typical for M. hyopneumoniae infection were observed 
and BAL from all pigs was negative for the presence of M. hyopneumoniae DNA. 
Detection of M. hyopneumoniae specific serum antibodies 
The serological profile of the animals is given in Table 1. Five piglets from the 
vaccinated and three from the non-vaccinated group were positive at 7 days of age. One non-
vaccinated animal remained positive until 36 days. Eleven out of seventeen and eight out of 
ten vaccinated pigs were positive at 30 and 58 days of age, respectively. From the age of 30 
days onwards, the average optical density values significantly differed between both groups. 
In the indirect ELISA, OD values for M. hyopneumoniae-specific IgM and IgA 
isotypes did not differ over time or among groups (data not shown). Results for IgG are 
summarized in Table 2. The OD value decreased in the non-vaccinated group (maternal 
immunity), whereas in the vaccinated group a decrease was observed until day 36 with a 
subsequent increase at day 58. The OD value of M. hyopneumoniae-specific IgG antibodies in 
the vaccinated group was higher during the study period, with significant differences at day 7 
and 58. 
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Table 1: Results of serology in non-vaccinated pigs (PBS) and in pigs vaccinated (VACC) against Mycoplasma hyopneumoniae at 7, 30, 36 and 
58 days of age. Animals were examined for the presence specific serum antibodies to M. hyopneumoniae using the IDEIA™ Mycoplasma 
hyopneumoniae ELISA Kit. 
 
a  
No animals were necropsied 
b 
Optical density at 450 nm  
c
 ± Standard deviation  
 
 
 
 
 
 Age of pigs 
7 30 36 58 
PBS VACC p  
value 
PBS VACC p 
 value 
PBS VACC p 
 value 
PBS VACC p  
value 
Number of seropositive 
overall pigs 3/16 5/17 0.400 1/16  11/17  0.001 1/13  13/14  0.000 0/9  8/10  0.001 
Number of seropositive 
necropsied pigs 
-
a
 - - 0/3 2/3 0.400 0/4  4/4  0.029 0/9  8/10  0.001 
Average OD value of 
sera for overall pigs 
2.08
b
 
(±0.21)
c
 
2.05 
(±0.24) 
0.82 1.26 
(±0.10) 
0.67 
(±0.12) 
0.000 1.25 
(±0.13) 
0.47 
(±0.05) 
0.000 1.66 
(±0.05) 
0.84 
(±0.19) 
0.021 
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Table 2: Mycoplasma hyopneumoniae-specific IgG antibody response (mean OD670nm ± 
standard error of the mean) in the serum at different time-points in the non-vaccinated (PBS) 
and vaccinated (VACC) pigs. At 7 days of age, pigs were injected intramuscularly with either 
PBS (n=16) or a commercial M. hyopneumoniae inactivated whole cell vaccine (n=17). 
 
Age of the pigs (days) PBS  VACC  p value 
7  0.35 ± 0.07
 
0.47 ± 0.08
 
0.015 
30  0.26 ± 0.09 0.43 ± 0.14 0.275 
36  0.21 ± 0.03 0.26 ± 0.02 0.248 
58  0.18 ± 0.01
 
0.48 ± 0.06
 
0.001 
 
Determination of T cell populations in different tissues 
The T-cell subset populations detected in blood, spleen, BLN and lung tissue are 
shown in Table 3. There were no statistically significant differences in percentage of 
lymphocytes subsets between groups at any time evaluated. We did detect a higher percentage 
of single positive CD8
+ 
in the vaccinated group at 30 days. On the other hand, the percentage 
of CD4
+
 cells was higher in the non-vaccinated group, with a numeric difference in the cells 
from the BLN (p=0.05), with a CD4
+
/CD8
+ 
ratio of 3.97 and 2.78 in the non-vaccinated and 
vaccinated group, respectively, at 30 days. The CD4
+
/CD8
+ 
ratio at 30 days of age was higher 
than 1 in all tissues, and there was a decrease of this ratio in the lung tissue at 58 days of age 
in both groups. Regarding the CD4
+
CD8
+ 
cells, a numeric difference was observed (p=0.05) 
in the BLN at 30 days of age, with a higher percentage of cells in the vaccinated group.  
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Table 3: Mean percentage ± standard error of the mean of T-cell subset populations per 10
6
 cells from the blood, spleen, bronchial lymph nodes 
(BLN) and lung, from the non-vaccinated (PBS) and vaccinated (VACC) pigs, assessed using flow cytometry.  
 
Tissue 30 days of age  58 days of age 
 PBS (n=3) VACC (n=3) p value  PBS (n=6) VACC  (n=5) p value 
CD4
+
        
Blood  39.6 ±  5.3 33.9 ± 7.2 0.513  44.5 ± 4.8 33.0 ± 5.7 0.088 
Spleen 32.0 ± 3.9 31.4 ± 1.5 0.827  31.9 ± 3.1 32.8 ± 1.3 0.749 
BLN 65.5 ±  1.1 58.9 ± 0.4  0.05  64.3 ± 4.7  61.2 ± 2.9 0.153 
Lung 39.6 ± 4.5 39.5 ±  3.6 0.827  22.3 ± 3.9 21.5 ± 1.9 0.806 
CD8
+
        
Blood  15.7±  2.5 17.3 ± 4.9 0.827  16.9 ± 4.5 20.6 ±  2.3 0.394 
Spleen 24.4 ±  4.4 25.7 ± 1.1 0.513  32.0 ± 6.4 26.0 ± 1.3 0.336 
BLN 16.5 ±  1.8 21.2 ± 1.3 0.127  17.4 ± 1.8 16.4 ± 0.9 0.886 
Lung 19.8 ± 1.9 25.1 ±  2.5 0.275  34.3 ± 6.8 37.6 ± 4.9 0.624 
CD4
+
CD8
+
        
Blood  7.4 ± 0.2 6.9 ±  0.7 0.658  3.5 ± 1.8 3.1 ± 0.8 0.100 
Spleen 17.4 ± 3.9 19.5 ± 2.2 0.513  10.7 ± 2.8 14.8 ± 2.1 0.336 
BLN 8.6 ± 0.6 13.3 ±  1.9 0.05  12.2 ± 2.9 17.1 ±  3.8 0.475 
Lung 16.4 ± 4.5 12.8 ± 0.1 0.513  9.7 ± 5.1 6.5 ± 0.4 1.000 
CD4
-
CD8
-
        
Blood  37.3 ± 2.8 41.9 ± 9.3 0.827  35.0 ± 9.5 42.2 ± 4.4 0.454 
Spleen 26.2 ± 1.7 23.4 ± 4.7 0.827  25.4 ± 3.3 26.4 ± 2.5 0.745 
BLN 9.5 ± 5.0 6.7 ± 0.9 0.127  6.1 ± 1.2  5.3 ± 0.7 0.668 
Lung 24.1 ± 2.6 22.7 ± 5.7 0.827  33.1 ± 7.9 34.4 ±  4.0 0.806 
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IFN-ɣ, IL-10 and IL-12 secreting cells  
The number of M. hyopneumoniae-specific IFN-ɣ, IL-10 and IL-12 secreting cells is 
shown in Table 4. A significantly higher number of IL-12 secreting cells was observed in the 
lung at 58 days of age, and a numeric difference in the spleen at 30 days of age (p=0.05) in 
the vaccinated group. In the BLN, a significantly lower number of IFN-ɣ secreting cells was 
observed in the vaccinated than in the non-vaccinated group at 36 days and a significantly 
higher number of IL-10 secreting cells in the vaccinated group at 58 days. 
IFN-ɣ, IL-10, IL-12 and TGF-β secretion in lymphocyte cultures 
IFN-ɣ, IL-10, IL-12 and TGF-β concentrations in supernatant of lymphocytes isolated 
from blood, spleen, BLN and lung is shown in Table 5. Significantly higher amounts of IL-12 
were obtained from BLN and lungs in the vaccinated group at 58 days of age. Not significant 
differences for IFN-ɣ, IL-10 and TGF-β, were observed. However, higher amounts of IL-10, 
statistically not significant, were detected in the BLN from the vaccinated group at all time 
points evaluated.  
M. hyopneumoniae-specific IgG, IgM and IgA in BAL fluid 
The three isotypes were detected in BAL fluid of vaccinated animals. M. 
hyopneumoniae specific IgM antibodies were detected at day 30 in all animals necropsied 
from the vaccinated group. For IgG, three out of 10 animals were positive at day 58 in the 
vaccinated group. In contrast, specific anti-M. hyopneumoniae IgA antibodies were detected 
at each time point in the vaccinated animals, with two out of three positive animals at day 30, 
four out four at day 36 and six out of ten animals at day 58. For isotypes and time points 
specified as above, a statistically significant difference (p<0.05) was observed between 
control and vaccinated animals when analysing OD values. 
IFN-ɣ, TNF-α, IL-1β and IL-6 concentrations in BAL fluid 
For IFN-ɣ at 30 days of age a significantly higher concentration was detected 
(p=0.046) in BAL fluid of the vaccinated group (Fig. 1a). For TNFα, a significantly higher 
concentration was measured at day 36 (p=0.040) in the vaccinated group, but the overall 
TNF-α concentration was quite similar between both groups over the study period (Fig. 1b). 
IL-1β and IL-6 (Fig. 1c and 1d) were detected at low levels in the vaccinated group, with a 
significant difference at day 36 for IL-1β (p=0.043).
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Table 4: Mean number of IFN-ɣ, IL-10 and IL-12 secreting cells per 105 monomorphonuclear cells ± standard error of the mean in blood, spleen, 
bronchial lymph nodes (BLN) and lung from the non-vaccinated (PBS) and vaccinated (VACC) pigs at different time points measured by 
ELIspot.  
 
 
30 days of age  36 days of age   58 days of age 
 PBS (n=3) VACC (n=3) p value  PBS (n=4) VACC  (n=4) p value  PBS (n=7) VACC  (n=8) p value 
IFN-ɣ            
Blood 0.6 ± 0.6 5.0 ± 3.7 0.178  3.0 ± 2.1 1.3 ± 0.6 0.881  7.9 ± 3.7 12.3 ± 4.6 0.409 
Spleen 0.0 ± 0.0 7.6 ± 3.9 0.246  11.0 ± 11.0 17.3 ± 5.5 0.237  8.7 ± 5.6 15.0 ± 9.3 0.676 
BLN 0.0 ± 0.0 0.3 ± 0.1 0.246  6.5  ±  4.3
 
0.0 ± 0.0
 
0.047  3.2 ± 1.8 9.6 ± 4.8 0.127 
Lung 1.2 ± 0.6 0.5 ± 0.2 0.275  5.7 ±  2.1 0.7 ± 0.5 0.137  0.1 ± 0.1 2.1 ± 1.1 0.055 
IL-10            
Blood 217.3 ± 17.9 252.3 ± 50.6 0.513  250.0 ± 170.9 106.3 ± 40.1  0.885  320.4 ± 105.7 390.6 ± 83.7 0.353 
Spleen 129.7 ± 50.6 95.3 ± 24.3 0.513  136.3 ± 49.7 118.8 ± 40.9 0.885  248.9 ± 91.1 161.6 ± 53.7 0.441 
BLN 6.7 ± 6.7 3.0 ± 2.1 0.817  6.3 ± 2.6 2.5 ± 1.4 0.225  0.4 ± 1.9
 
10.0 ±  6.0
 
0.031 
Lung 39.7 ± 20.0 60.3 ± 19.9 0.275  123.8 ± 49.9 191.3 ± 58.3 0.248  91.1 ± 26.3 173.8 ± 43.8 0.132 
IL-12            
Blood 0.4 ± 0.2 0.3 ± 0.18 0.637  0.3 ± 0.3 0.0 ± 0.0 0.317  12.9 ± 7.0 11.6 ± 3.9 0.723 
Spleen 0.3 ±0.2 5.3 ± 2.64 0.050  9.0 ± 2.8 12.3 ± 4.9 0.663  34.6 ± 14.8 23.9 ± 8.9 0.350 
BLN 0.0 ± 0.0 0.13 ± 0.13 0.317  1.0 ±  0.6 0.8 ± 0. 3 0.760  7.3 ± 3. 7.0 ± 2.7 0.770 
Lung 0.1 ± 0.1 0.1 ± 0.03 0.346  1.8 ± 1.2 1.5 ± 1.5 0.741  2.3 ± 1.6
 
8.0 ± 2.6
 
0.036 
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Table 5: Mean IFN-ɣ, IL-10, IL-12 and TGF-β concentration ± SEM (pg/ml) in lymphocyte cultures from blood, spleen, bronchial lymph nodes 
(BLN) and lungs in the non-vaccinated (PBS) and vaccinated (VACC) pigs at different time points measured by ELISA. 
 Day 30 Day36   Day 58 
 PBS (n=3) VACC (n=3) p value  PBS (n=4) VACC  (n=4) p value  PBS (n=7) VACC  (n=8) p value 
IFN-ɣ            
Blood 81.1 ± 5.4 72.9 ± 20.4 0.513  141.2 ±  36.0 103.5 ± 32.1 0.149  101.9 ± 7.1 103.2 ± 4.9 0.817 
Spleen 65.3 ± 4.8 102.8 ± 16.6 0.127  151.0 ± 54.1 142.3 ± 48.4 0.100  102.1 ± 8.6 105.8 ± 8.1 0.817 
BLN 142.6 ±  9.2 126.4 ± 6.4  0.275  135.6 ± 39.6 130.9 ± 39.3 0.564  100.3 ± 6.8 104.7 ± 7.4 0.817 
Lung 77.1 ± 13.5 73.7 ± 11.6 0.827  154.0 ± 48.4 111.3 ± 43.4 0.248  93.9 ± 5.2 105.9 ± 6.2 0.083 
IL-10            
Blood 1196.3 ± 75.1 1463.8 ± 300.3 0.513  1398.0 ± 122.9 1346.0 ± 23.3 0.773  1455.1 ± 188.3 133.1 ± 137.9 0.817 
Spleen 2002.3 ± 837.6 2957.7 ± 295.8 0.275  1371.3 ± 215.8 1358.8 ± 63.2 0.773  1475.3 ± 203.4 1669.1 ± 119.2 0.563 
BLN 499.0 ± 85.7 902.3 ± 247.2 0.127  527.8 ± 117.7 547.3 ± 119.1 0.564  489.4 ± 123.4 617.1 ± 94.0 0.298 
Lung 900.0 ± 257.0 960.3 ± 161.5 0.827  1238.8 ± 219.0 1042.0 ± 112.2 0.248  904.3 ± 124.9 944.25 ± 115.10 0.728 
IL-12            
Blood 102.3 ± 51.9 55.3 ± 35.3 0.376  170.3 ± 116.4 278.0 ± 180.5 0.758  232.3 ± 93.2 178.0 ± 75.6 0.550 
Spleen 1933.7 ± 641.9 1807.7 ± 788.1 0.827  1345.8 ± 212.7 3367.5 ± 2015.0 0.564  1539.1 ± 422.5 2532.4 ± 338.8 0.132 
BLN  0.0 801.3 ± 737.8  0.121  590.0 ± 276.8 452.0 ± 285.2 0.663  472.7 ± 230.1
 
1196.0 ± 210.7
 
0.028 
Lung 268.7 ± 77.4 541.30 ± 185.0 0.275  155.0 ± 54.9 337.8 ± 129.3 0.191  255.9 ± 83.5
 
702.4 ± 119.9
 
0.018 
TGF-β            
Blood 308.0 ±  252.2 405.7 ± 225.0 0.275  266.8 ± 38.9 481.0 ± 150.4 0.149  709.0 ± 102.9 447.1 ± 119.4 0.105 
Spleen 239.3 ±  125.6 152.7 ±  55.4 0.513  263.0 ± 121.3 56.0± 33.7 0.081  252.9 ± 142.7 304.0 ± 169.9 0.896 
BLN 63.3 ±  32.2 158.0 ±  51.0 0.275  296.8 ± 85.2 429.0 ± 130.7 0.386  737.0 ± 152.5 416.0 ± 123.6 0.064 
Lung 343.0 ±  214.1 465.7 ±  136.0 0.513  252.3 ± 100.5 259.3 ± 188.7 0.564  364.0 ± 194.0 382.9 ± 151.5 0.858 
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A.                                                                                                                                    B.  
 
 
 
 
 
 
C.                                                                                                                                    D. 
 
 
 
 
 
                                                                                                                               
Figure 1: Mean (and SE) of IFN-ɣ (A), TNF-α (B), IL-1β (C) and IL-6 (D) secretion in BAL fluid measured by ELISA (OD450nm) from the  
non-vaccinated (PBS) and vaccinated (VACC) pigs, at the different time points. Pigs were vaccinated at 7days of age with a commercial M. 
hyopneumoniae inactivated whole cell vaccine.
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Discussion 
As expected, vaccination with the current bacterin induced the production of serum 
antibodies against M. hyopneumoniae. Almost 70% of the pigs were positive within three 
weeks after vaccination and 80% of the animals were positive at the end of the study. These 
results are in agreement with other studies (Sibila et al., 2007; Villarreal et al., 2011) where 
one-shot vaccination at 7 days of age induced seroconversion by the 25
th 
day of age. However, 
previous challenge experiments showed that the concentration of serum antibodies is not 
directly related to protection against M. hyopneumoniae infections (Djordjevic et al., 1997; 
Thacker et al., 1998).  
Studies carried out in vaccinated (Borghetti et al., 2006; Kick et al., 2011) and non-
vaccinated pigs (Stepanova et al., 2007) showed that different T cell subsets may be present in 
the peripheral blood and secondary lymphoid tissues. Our results were partially consistent 
with these reports, with an increase of the percentage of CD8
+ 
T cells with increasing age in 
both groups and in all tissues (except in the BLN of vaccinated group). Previous reports also 
showed a decrease of CD4
+ 
and an increase in the percentage of CD4
+
CD8
+ 
T cells with 
increasing age (Borghetti et al., 2006; Kick et al., 2011). In our studies, this decreased 
percentage of CD4
+
 cells was seen in lung tissue and an increased percentage of CD4
+
CD8
+ 
T 
cells was observed in the BLN.  
In most tissues the percentage of CD8
+ 
T cells was highest in the vaccinated group and 
at day 58, the percentage of CD8
+ 
cells prevailed over CD4
+ 
cells in the lung tissue. CD8
+ 
T 
cells may modulate the inflammatory response through the production of IFN-ɣ and other 
cytokines, minimizing damage due to the CD4
+ 
T (Th) cell mediated inflammatory responses 
(Jone and Simecka, 2003). This might be one of the reasons why vaccinated animals develop 
less severe clinical symptoms and lung lesions after challenge with M. hyopneumoniae 
(Meyns et al., 2006; Villarreal et al., 2011). 
At 58 days of age, a significantly higher number of IL-10 secreting cells was detected 
in the BLN tissue of the vaccinated animals. Since IL-10 has an anti-proliferative effect, that 
can prevent the pathological effects of the inflammatory cytokines (Conti et al., 2003), this 
may also play a role in the reduction of lung tissue damage after infection of vaccinated 
animals which has been described in several studies (Meyns et al., 2006; Villarreal et al., 
2011). Induction of IL-10 secretion by vaccination may also result in a lower influx of 
macrophages in the bronchoalveolar lymphoid tissue in vaccinated pigs compared to non-
vaccinated animals, after experimental infection with M. hyopneumoniae, as described by 
Vranckx et al. (2012). 
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To evaluate the specific M. hyopneumoniae cell-mediated immune response induced 
by vaccination, ELISA and ELIspot were performed to quantify IFN-ɣ, IL-10 and IL-12 
cytokines and cytokines producing cells. Vaccinated pigs showed significantly higher 
amounts of IL-12 in BLN and lung tissues. Production of IL-12 by macrophages and B cells 
has been demonstrated to be important in the induction of a Th1 immune response (Yang et 
al., 2004). Furthermore, this cytokine stimulates IFN-ɣ production and enhances CD8+ 
cytotoxicity, both contributing to maintaining the cell mediated immunity (Park and Scott, 
2001). Indeed, at day 58, the number of IFN-ɣ secreting cells was numerically higher 
(p=0.055) in the lungs, and significantly higher in the BAL fluid of the vaccinated group at 
day 30, indicating that the vaccine also induced a local cellular immune response. 
The highest concentrations of IL-1β and IL-6 were detected in the BAL fluid of the 
non-vaccinated group, with a significantly higher value at day 36 for IL-1β. This may suggest 
a regulatory effect of the vaccine in the release of these cytokines. Increased levels of IL1 and 
IL6 were indeed observed in BAL fluid of M. hyopneumoniae infected pigs (Choi et al., 2006; 
Thacker et al., 2000) and excessive levels of these cytokines have been associated with tissue 
damage and even death of the host (Asai et al., 1993; Okada et al., 2000). 
In the present study, vaccination was able to stimulate IgG, IgM and IgA specific M. 
hyopneumoniae antibodies in the BAL fluid. IgA specific antibodies were detected at all time 
points investigated. Specific antibodies in the BAL fluid may play an important role in 
protection against M. hyopneumoniae infections (Thacker et al., 2000). M. hyopneumoniae is 
a mucosal pathogen that adheres to the ciliated epithelial cells of the respiratory tract. Local 
IgA secretion prevents the adhesion of mycoplasmas to the ciliated epithelium, and IgG 
enhances their phagocytosis by alveolar macrophages (Sheldrake et al., 1990).  
 In conclusion, the present study documented that the vaccine induced both local and 
systemic immune responses involving both specific antibodies and cellular immunity. Further 
studies are necessary to determine the role of these components of the host immune response 
in protection induced by the vaccine. 
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Abstract 
Multi-antigen chimera with three antigens of Mycoplasma hyopneumoniae (R1, P42 and 
NrdF) and the mucosal adjuvant Escherichia coli heat labile enterotoxin B subunit (LTB) was 
constructed, and its antigenic and immunogenic properties were evaluated in mice and pigs. In 
addition, we compared the effect of the fusion and co-administration of these proteins. 
Antibodies against each subunit recognized the chimeric protein. Intranasal and intramuscular 
immunization of mice with the chimeric protein significantly increased the levels of mice IgG 
and IgA, in serum and tracheobronchial lavages, respectively. Swine immunized with the 
chimeric protein developed an immune response against all M. hyopneumoniae antigens 
present in the fusion with statistically significant difference (p<0.05). The adjuvant rLTB 
stimulated the immune response in both, fused and co-administered antigens, with better 
results with the chimeric protein. This multi-antigen is a promising vaccine candidate that 
may help to control M. hyopneumoniae infection. 
Keywords: Fused protein, swine enzootic pneumonia, adjuvant, bacterial enterotoxins 
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Introduction 
Mycoplasma hyopneumoniae, the primary pathogen of enzootic pneumonia (EP), 
occurs worldwide and causes major economic losses to the pig industry (Thacker and Minion, 
2010). Vaccination combined with hygiene and management procedures is the most effective 
way to control the disease (Maes et al., 2008). The current commercial vaccines consist of 
whole-cell adjuvanted formulations, and provide only partial protection. They do not prevent 
colonization of M. hyopneumoniae in the respiratory tract, do not significantly reduce 
transmission, and are costly to produce (Haesebrouck et al., 2004).  
 Major efforts have been made towards the development of improved vaccines using 
diverse strategies, mainly through the use of subunit vaccines, rather than those based on 
whole bacterial cells. Subunit vaccines are considerably safer, more specific, with less adverse 
reactions and with the possibility of large scale production of recombinant proteins by 
biotechnological process (Soria-Guerra et al., 2011). They can also be easily manipulated and 
administered to the animal through various routes such as oral, nasal, intramuscular, or 
subcutaneous. In addition, potentially multiple antigens can be delivered at the same time in a 
single dose of immunization as chimeric proteins (Liljeqvist and Stahl, 1999). Chimeric 
proteins carrying epitopes from different pathogens, linkers, or adjuvant sequences offer an 
increased immunogenicity of recombinant antigens, and can also elicit a broad cellular and/or 
humoral immune response (Berzofsky et al., 2001). 
 Considering that genetically engineered vaccines composed of a single recombinant 
antigen are poorly immunogenic, it is important to increase their immunogenicity by 
combining with appropriate adjuvants (Soria-Guerra et al., 2011). One strategy has been to 
employ bacterial enterotoxins such as cholera toxin (CT) from Vibrio cholera or the related 
subunit B of heat-labile enterotoxin of Escherichia coli (LTB). These have been shown to be 
highly immunogenic, demonstrate potent immunomodulatory activity with a range of antigens 
either fused or co-administered to them, in different animal models, enhance immunogenicity 
as well as to confer protective efficacy (Conceição et al., 2006; da Hora et al., 2011; 
Grassmann et al., 2012; Qiao et al., 2009; Zhou et al., 2009). They are considered as potent 
mucosal and parenteral adjuvants (Cox et al., 2006; da Hora et al., 2011; Simmons et al., 
2001), which have been demonstrated to enhance mucosal immunoglobulin A (IgA) as well 
as systemic antibody responses. 
The reverse vaccinology approach revealed that several M. hyopneumoniae antigens 
might be potential candidates to be included in subunit vaccines (Fagan et al., 2001; 
Marchioro et al., 2012; Ogawa et al., 2010; Okamba et al., 2010; Okamba et al., 2007; 
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Shimoji et al., 2003; Simionatto et al., 2012). Some of these antigens include the P97 adhesin 
and its C-terminal region (P97R1) which plays a role in adherence of the pathogen to the 
respiratory tract of the host, the ribonucleotide reductase (NrdF) and the heat shock protein 
P42. P97 (Shimoji et al., 2003), P97R1 (Ogawa et al., 2010; Okamba et al., 2010) and NrdF 
(Fagan et al., 2001) have been investigated as single antigens in different vaccine 
formulations. Some of these formulations (P97 and Nrdf) were able to induce specific 
immune responses in pigs (Fagan et al., 2001; Shimoji et al., 2003), but provided only limited 
protection against pulmonary lesions caused by M. hyopneumoniae infection. However, 
improved strategies for efficient antigen presentation and immune responses are still needed 
to increase protective immunity against infection.  
The aims of the present study were (i) to produce a recombinant chimeric protein 
composed of the P97R1, P42 and NrdF antigens of M. hyopneumoniae fused to LTB, (ii) to 
evaluate the capacity of this chimeric protein to induce a specific immune response in mice 
and pigs and (iii) to compare the effect of the fusion and co-administration of these proteins as 
well as the adjuvant effect of LTB. 
 
Materials and methods 
Bacterial strains and growth conditions 
Escherichia coli TOP 10 (Invitrogen) and BL21 (DE3) RIL (Stratagene) were grown 
in Luria Bertani (LB) medium supplemented with ampicillin (100 µg.ml
-1
), as required, and 
incubated in shaker at 37 °C and 200 rpm. 
Plasmids, DNA procedures and electrotransformation 
The plasmids encoding the gene p42, nrdf and p97(r1) of M. hyopneumoniae strain 
7448 (GenBank accession number NC007332) and the ltb of E. coli were cloned in our 
laboratory as previously described (Conceição et al., 2006; Simionatto et al., 2010). A 
synthetic chimeric gene encoding the E. coli ltb, the R1 repeat region of p97 (r1), the C-
terminal portion of heat shock protein gene p42 and the ribonucleotide reductase nrdF of M. 
hyopneumoniae was obtained from Epoch Life Science (Texas, US). The sequence encoding 
the chimeric gene was provided with restriction sites necessary for further cloning step in E. 
coli expression vector - pAE (Ramos et al., 2004). The chimeric gene was excised from the 
pUC18 plasmid provided by Epoch Life Science using the BamHI and KpnI restriction 
enzymes and cloned into corresponding sites of pAE E. coli expression vector. E. coli Top 10 
competent cells were transformed by electroporation with ligation products as described by 
Sambrook and Russel (2001). Recombinant clones were selected and plasmid DNA was 
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extracted and characterized by digestion with restriction enzymes and DNA sequencing using 
a MegaBACE 500 DNA sequencer and the Dynamic ET-terminator technology 
(GEHealthcare).  
Expression, solubility testing and purification of recombinant proteins 
The recombinant vectors pAE/ltb, pAE/p42, pAE/nrdF, pET/r1, and 
pAE/ltbr1p42nrdF were used to transform E. coli BL21 (DE3) Ril. The 6X His-tagged 
recombinant LTB (rLTB), recombinant P42 (rP42), recombinant NrdF (rNrdF), recombinant 
R1 (rR1) and recombinant chimeric protein (rLTBR1P42NrdF) were expressed and purified 
by affinity chromatography as previously described (Marchioro et al., 2012; Simionatto et al., 
2010). Fractions containing recombinant proteins were identified by SDS-PAGE and 
quantified by BCA™ Protein Assay (Pierce) following the manufacturer's instructions. 
Characterization of the recombinant chimeric protein by Western blot 
Purified recombinant proteins rLTB, rR1, rP42, rNrdF and chimeric protein 
rLTBR1P42NrdF were applied to 12% SDS-PAGE and electro-transferred on a nitrocellulose 
membrane for characterization by Western blot analysis as described elsewhere (Simionatto et 
al., 2010). The antibodies and dilutions used were: monoclonal anti-R1 (1:4000), polyclonal 
anti-P42 (1:100), polyclonal anti-NrdF (1:100) or polyclonal anti-LTB (1:100) and a HRP-
conjugate goat anti-mouse (Sigma Aldrich) diluted 1:6000.  
 The ability of rLTBR1P42NrdF to bind to GM1-ganglioside was determined by an 
enzyme-linked immunosorbent assay (ELISA) as previously described (Grassmann et al., 
2012), using the following antibodies and dilutions: monoclonal anti-R1 (1:4000), polyclonal 
anti-P42 (1:100), polyclonal anti-NrdF (1:100) or rabbit IgG anti-cholera toxin (1:6000) 
followed by a goat IgG anti-mouse or anti-rabbit IgG peroxidase conjugated diluted 1:6000. 
Wells with GM1 but without proteins and wells without GM1 but with proteins were used as 
controls. 
Immunogenicity in mice  
Animal experiments were carried out according to the guidelines of the Ethical 
Committee in Animal Experimentation of the Federal University of Pelotas. Female BALB/c 
mice aged 7 to 8 weeks were used in the experiment. Eight groups of mice with eight animals 
each were inoculated intramuscularly (IM) and or intranasally (IN) on days 0, 15 and 30 with 
20 µg of recombinant proteins as follow: (1) rLTB IN; (2) rLTB IM; (3) rLTBR1P42NrdF 
(chimeric protein) IN; (4) rLTBR1P42NrdF IM; (5) rR1+rP42+rNrdF+ rLTB (co-
administered proteins with adjuvant) IN; (6) rR1+rP42+rNrdF+ rLTB IM; (7) 
rR1+rP42+rNrdf (co-administered proteins without adjuvant)  IN; (8) rR1+rP42+rNrdF IM. 
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For groups 5, 6, 7 and 8, the doses of each protein were calculated in order to have the 
equivalent amount of each protein as contained in the chimeric protein. Blood samples were 
collected from the retro-orbital sinus at 0, 15, 30 and 45 days post inoculation (DPI). The sera 
were processed and stored at -20 °C until tested. On day 45, the animals were euthanized and 
in four mice of each group, tracheobronchial lavages were collected. Tracheobronchial 
lavages were carried out by flushing three times with a total volume of 0.5 ml of PBS 
containing 0.5% bovine serum albumin (BSA) and a protease inhibitor PMSF (inhibitor 
phenylmethylsulfonyl fluoride; Sigma) 0.1 mM  and stored at -20 °C.  
To assess the immunogenicity of chimeric protein, sera from mice (diluted 1:100) 
before and 30 days after the first immunization with this protein were confronted with 2 µg of 
extract of different M. hyopneumoniae strains (J, 7448 and USP strain) by Western blot as 
described above. 
Immunogenicity in pigs 
Three M. hyopneumoniae free piglets were used to check the immunogenicity of the 
chimeric protein. Animals were inoculated intramuscularly with three doses of 300 µg of the 
chimeric protein in 10 days interval. Serum samples were collected and systemic IgG was 
measured by indirect ELISA. 
Antibody assays  
The specificity of the antibodies elicited by immunization with the chimeric protein 
and recombinant proteins co-administrated in mice and pigs was determined by an indirect 
ELISA. Microtiter plates were coated with 100 µL of each recombinant protein at 
concentrations ranging from 10 to 100 ng/well in 0.1 M sodium carbonate buffer (pH 9.6),  at 
4 °C overnight. The plates were washed three times with PBST and incubated with 200 µL of 
5% blocking buffer at 37 °C for 2 h. After washing with PBST, wells were incubated with 
mice or pig sera (diluted 1:100 in blocking buffer) and or tracheobronchial lavages 
(undiluted), at 37 °C for 1 h. After washing three times with PBST, goat anti-mouse or anti-
pig IgG peroxidase conjugated (Sigma Aldrich) and or anti-mouse IgA peroxidase conjugate 
(Sigma Aldrich) diluted 1:6000 was added and the plate was incubated at 37 °C for 1 h. The 
reactions were developed with o-phenylenediaminedihydrochloride (Sigma) and hydrogen 
peroxide, after PBST washes. The color reaction was allowed to develop for 15 min before 
being stopped with 50 µl of sulfuric acid 1 N. Absorbance was determined at 492 nm with a 
microplate reader (Multiskan MCC/340, Titertek Instruments). Mean values were calculated 
from serum samples assayed in triplicate. The IgG isotype profiles were also determined, anti-
mouse IgG was substituted by antibodies supplied by IsoQuick™ Kit for Mouse Monoclonal 
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Isotyping (Sigma Aldrich) according to the manufacturer’s instructions using mice serum 
samples obtained at day 0 and 45.  
Statistical Analysis 
All data were expressed as mean ± standard deviation. Experimental values of IgG 
antibody responses were analyzed by analysis of variance (ANOVA), data were log-
transformed to conform to the normality and variance requirements of parametric testing. If 
the p value from the ANOVA was less than 0.05, pairwise comparisons of the different 
treatment groups were performed by Scheffé test at a rejection level of a p-value < 0.05. The 
non-parametric Kruskal-Wallis test was used for comparison of IgA antibody responses. 
Statistical analyses were performed using SPSS Statistical Software 19.  
 
Results 
Recombinant proteins expression and antigenicity 
Protein electrophoresis showed bands with apparent molecular masses of each 
recombinant protein. rLTB, rP42, rNrdF and rLTBR1P42NrdF were expressed in inclusion 
bodies and required the addition of the denaturing agent N-lauroyl-sarcosine for purification, 
while rR1 was expressed and purified as a soluble protein. The antigenicity of the 
rLTBR1P42NrdF chimeric protein was confirmed by Western blot using anti-R1, anti-P42, 
anti-NrdF and anti-LTB antibodies. The antibodies recognized all the proteins contained in 
the chimeric protein.  
The GM1-ELISA with recombinant proteins revealed GM1-binding affinity of rLTB 
and rLTBR1P42NrdF, showing that the fusion did not impair the binding affinity of LTB 
(data not shown). 
Immunogenicity in mice 
The capacity of the chimeric protein and the co-administrated proteins to induce serum 
IgG antibodies in mice was evaluated by ELISA. All formulations stimulated detectable 
antibodies against each protein, showing that the chimeric and co-administered recombinant 
proteins were immunogenic for mice. Besides, antibodies induced by the immunization with 
the chimeric protein were able to react with all M. hyopneumoniae strains tested by Western 
blot, with a weaker reaction with the non-pathogenic J strain (data not shown). 
In the groups immunized IM, the IgG level was higher when compared with IN route, 
as well as the response to the protein rP42 was higher when compared with the other two 
proteins (Fig. 1A, 1B, 1C).  The anti-rP42 and anti-rR1 antibodies were higher in sera from 
mice vaccinated with the chimeric protein, with significant differences at 30 and 45 DPI 
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(p<0.05) (Fig. 1A, 1B and 1D). Anti-rNrdF antibodies in the serum of animals inoculated IM 
with the chimeric protein had the lowest reactions compared with the other two proteins, with 
highest levels of antibodies in the group inoculated with the proteins co-administrated with 
LTB (Fig. 1C). Nevertheless, no difference between the chimeric protein group and the group 
that received the proteins co-administered with adjuvant LTB was found at 45 DPI against all 
the three antigens. Intranasal immunization did not show significant differences in antibody 
production against rR1 and rNrdF proteins. 
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Figure 1. Absorbance at 492 nm of serum of mice immunized intramuscularly (A, B and C) or intranasally (D) with rLTB, chimeric protein, 
rLTB+R1+P42+NrdF or with rR1+P42+NrdF at 0, 15 and 30 days post inoculation (DPI). On days 0, 15, 30 and 45, sera of mice were obtained 
and the levels of anti-rP42, rR1 and rNrdF were determined by indirect ELISA. Microtiter plates were coated with recombinant proteins and 
incubated with sera from immunized mice diluted 1:100. Anti-mouse IgG peroxidase conjugated (1:6000) was added as secondary antibody. 
Data represent the mean and standard deviation OD492 (n=8) of mice serum. All reactions were performed in triplicate. *p<0.05 compared with 
the mice treated with rLTB, rLTB+R1+P42+NrdF or with rR1+P42+NrdF.
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Mucosal IgA production in tracheobronchial lavages from different groups at 45 DPI 
was also tested (Fig. 2). No differences between IM or IN administration were detected and 
significant differences were only found in the IgA antibodies against the rP42. Levels of IgA 
anti-rP42 antibodies in groups vaccinated with chimeric protein by both routes of 
immunization showed the highest levels, with statistically difference from the control group 
(LTB by IM or IN) and from the group that received co-administered protein without adjuvant 
by IM (p<0.05). The anti-rR1 and anti-rNrdF IgA antibodies did not show significant 
differences between the groups evaluated. 
 
 
Figure 2. Absorbance at 492 nm of tracheobronchial lavages from mice immunized 
intramuscularly (IM) or intranasaly (IN) with rLTB, chimeric protein, rLTB+R1+P42+NrdF 
or with rR1+P42+NrdF at 0, 15 and 30 DPI. On day 45 the animals were euthanized, 
tracheobronchial lavages collected and the levels of anti-rP42 were determined by indirect 
ELISA. Microtiter plates were coated with recombinant protein and incubated with undiluted 
tracheobronchial lavage. Anti-mouse IgA peroxidase conjugated (1:6000) was added as 
secondary antibody. Data represent the mean and standard deviation OD492 (n=4) of mice 
tracheobronchial lavage. All reactions were performed in triplicate. *p<0.05 compared with 
the mice treated with rLTB (IM and IN), rLTB+R1+P42+NrdF (IN) or with rR1+P42+NrdF 
(IM). 
Analysis of IgG isotypes showed that all the groups induced predominantly IgG1. By 
IM, the group inoculated with the chimeric protein showed the highest seroconversion for 
both isotypes against all the proteins, with significant differences to all the groups (p<0.05). 
Although the induction of IgG1 was higher (Fig. 3A), an induction of IgG2a (Fig. 3B) was 
observed. In the groups immunized IN, highest and significant seroconversion against the 
protein rP42 was observed in the group immunized with chimeric protein, that showed 
significant differences within all the groups (p<0.05) for both isotypes (Figs. 3C and D).
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 Figure 3. Recombinant proteins-specific IgG1 and IgG2a antibodies determined by ELISA. Microtiter plates were coated with recombinant 
proteins (rR1, rP42 and rNrdF). Recombinant proteins were incubated with sera (diluted 1:100) from immunized mice intramuscular (A and B) 
and intranasal (C and D). Goat anti-mouse IgG1 and IgG2a supplied by IsoQuick™ Kit for Mouse Monoclonal Isotyping (Sigma) were used as 
secondary antibody. Data represent the mean OD492 (n=8) of mice serum collected at 45 DPI divided by mean OD492 of mice serum collected at 
day 0. All reactions were performed in triplicate. *p<0.05 compared with the mice treated with rLTB, rLTB+R1+P42+NrdF and with 
rR1+P42+NrdF.
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Immunogenicity in pigs 
The humoral immune response induced by the chimeric protein administered IM was 
evaluated in pigs by ELISA (Fig. 4). The fusion induced a humoral immune response. 
Similarly to what was observed in mice, the antibodies anti-rP42 showed higher levels when 
compared to the other proteins, although antibodies anti-NrdF and anti-R1 were also detected 
with significant difference between the day 0 (pre-immune) and 30 DPI. 
 
 
 
 
 
 
 
     
 
Figure 4. IgG absorbance at 492 nm of immunized pigs. Pigs were intramuscularly 
immunized with chimeric protein (rLTBR1P42NrdF) at days 0, 20 and 30. On days 0 and 45 
serum was collected and the levels of anti-rP42, rR1and rNrdF were determined by ELISA. 
ELISA antibody titers are presented as the mean from all the pigs on day 0 and 45. *p<0.05 
compared with the pigs serum on day 0. 
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Discussion 
In the present study, a recombinant chimeric protein (rLTBR1P42NrdF) was produced 
that induced humoral and mucosal immune responses in mice by either IN or IM 
immunization and that a humoral immune response in pigs by IM immunization. Humoral and 
mucosal immune responses were characterized by the production of high levels of anti rR1, 
rP42 and rNrdF IgG in the sera and IgA antibodies in tracheobronchial lavage of vaccinated 
animals. The main strategy was to design a chimeric protein carrying different antigens from 
M. hyopneumoniae and an adjuvant molecule to increase the immunogenicity of the 
recombinant antigens. Some of these antigens (P97 and NrdF) have previously been shown to 
induce specific immune responses in pigs (Fagan et al; Shimoji et al., 2003), and the heat 
shock protein P42 has been considered a good immunogen in several studies (Simionatto et 
al., 2012; Chen et al., 2003). 
Foreign antigens fused to recombinant LTB might constitute useful experimental 
mucosal vaccines (da Hora et al., 2011). LTB has been shown to be a potent mucosal adjuvant 
toward co-administered or fused unrelated antigens (Grassmann et al., 2012; Liu et al., 2011; 
Zhou et al., 2009). Foreign antigens fused to the LTB subunit can be delivered across the 
mucosal epithelium to the underlying mucosa-associated lymphoid tissue to stimulate the 
mucosal immune system by mediating the induction of antigen-specific serum IgG and 
mucosal IgA (Kim et al., 2011). Our results demonstrated that the presence of LTB, in either 
co-administered or fusion proteins, produced significantly higher levels of IgG and IgA 
antibodies in IN and IM immunization, although these levels differed between each antigen, 
with higher antibody levels against the rP42. However, no significant differences were found 
between co-administered or fusion proteins in some assays.  In most assays, the fusion protein 
was more efficient. This corroborates with previous studies (Grassmann et al., 2012; Zhou et 
al., 2009), highlights the performance and advantages of chimeric proteins for use in vaccine 
development. 
A major challenge for current vaccine development is the fact that many new subunit 
vaccines based on recombinant proteins are poorly immunogenic and therefore require to be 
formulated with adjuvants (Wilson-Welder et al., 2009). In this study the IgG levels in mice 
serum were significantly higher in the groups immunized IM when compared to the groups 
that received the same composition IN. Within the groups inoculated IM, the highest antibody 
response against rP42 and rR1 was found in the chimeric protein group. The antibody 
production against rNrdF was higher in the group that received antigens with adjuvant without 
fusion, however there was no difference between fusion and co-administration. Within the IN 
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immunized groups, significantly higher responses against the rP42 were observed in the 
chimeric group. The IgA antibody levels against each protein in the tracheobronchial lavage 
followed the same trend as the IgG levels in the serum of the groups inoculated by intranasal 
route, suggesting a correlation in the production of these two classes of antibodies. These 
results evidenced the effect of rLTB in either co-administered or fusion antigens as 
demonstrated by Grassmann and collaborators (2012), and confirmed the efficacy as a 
mucosal and systemic adjuvant as already described. 
The mechanisms by which the enterotoxin-based adjuvant exerts immunomodulating 
effects are not fully characterized (da Hora et al., 2011). It has already been shown that LTB 
can increase both T helper type 1 and 2 (Th1 and Th2) associated cytokine response to LTB-
fused antigens, once IFN-, IL-2, IL-4, and IL-10 were specifically and significantly induced 
by a multi-epitope vaccine against Helicobacter pylori (HUepi) fused to LTB, HUepi-LTB, in 
mice immunized orally (Zhou et al., 2009). Even though no cytokine production was 
measured in the present study it is commonly accepted that Th1 cells are preferentially 
involved in cell-mediated immunity, by the production of IgG2a antibodies, while Th2 cells 
are more effective in the regulation and support of B-cell responses, resulting in the 
production of IgG1 antibodies (Mosmann et al., 1989). The results of IgG1 and IgG2a 
seroconversion in mice immunized IM showed that the chimeric protein was able to induce 
both isotypes, significantly better than the other groups. In the groups inoculated IN, 
significant differences were only found in the response against rP42, with higher levels in the 
group inoculated with the chimeric protein. These results indicate a mixed Th1 and Th2 
response, mainly against the rP42.  
The chimeric protein was also able to induce specific IgG antibodies in pigs, 
demonstrating the same profile as in mice. Significant differences were detected between pre-
immune and immune antibody levels in the serum against all antigens comprising the 
chimeric protein, with higher levels of antibodies against rP42. As for many infectious 
diseases, vaccination remains the approach for prevention and control of EP and the 
eradication of the pathogen has been proposed to depend on both the presence of serum 
antibody and an increase in cell-mediated immunity during mycoplasmal infection (Thacker 
et al., 2000), however, the actual contribution of both types of immune response in the 
protection against M. hyopneumoniae infections is not clearly defined (Okamba et al., 2010).  
The production of anti P42-specific antibodies in the immunized mice and pigs 
confirmed that P42 induced a stronger immune response when compared with the other two 
antigens. This result corroborates with previous studies by our group, where the P42 was one 
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of the most immunogenic antigens among 34 different M. hyopneumoniae proteins evaluated 
(Simionatto et al., 2012). These results can be attributed to the fact that P42, as a heat shock 
protein, may contribute to an additional immunostimulatory effect. Heat shock proteins have 
been shown to present multiple B-cell and T-cell epitopes (Yagihashi et al., 1984) and have 
also been used as an adjuvant to enhance cell-mediated immune responses in DNA vaccines 
(Chen et al., 2000). 
The Western blot characterization suggested that the recombinant chimeric protein 
retained antigenic epitopes present on native proteins. The chimeric protein was identified by 
specific sera against each subunit. In addition, serum of mice inoculated with the chimeric 
protein reacted with several M. hyopneumoniae strains. There was a weak reaction with the 
non-pathogenic J strain, indicating that the immune response induced by this protein is able to 
recognize the native antigens R1, P42 and NrdF. Immunoblotting results showed that the 
recombinant chimeric protein displayed good immunogenicity and antigenicity, and LTB 
retained the ability to bind to GM1. 
In conclusion, the study described the design, expression and immunological response 
of a chimeric recombinant protein comprising three M. hyopneumoniae antigens and the 
adjuvant LTB. The chimeric protein exhibited antigenic profiles similar to those of the 
original proteins, and the antigens included induced an immune response in mice and in pigs. 
To our knowledge, this is the first demonstration of a multivalent subunit recombinant 
vaccine synthesized as a single molecule for M. hyopneumoniae. This approach may result in 
a formulation that could improve the protection against enzootic pneumonia in pigs.  Further 
research will focus on the protective immunity of the vaccine against experimental M. 
hyopneumoniae in pigs. 
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Abstract 
Mycoplasma hyopneumoniae is the etiological agent of swine enzootic pneumonia 
(EP), a chronic respiratory disease which causes significant economic losses to the swine 
industry worldwide. More efficient strategies for controlling this disease are necessary. In this 
study, we cloned 17 genes coding for transmembrane proteins from M. hyopneumoniae, 
among which six were successfully expressed in E. coli and had their immunogenic and 
antigenic properties evaluated. All proteins were immunogenic in mice and sera from 
naturally infected pigs reacted with the recombinant proteins, suggesting that they are 
expressed during infection. These antigens may contribute to the development of new 
recombinant vaccines and diagnostic tests against EP. 
Keywords: Mycoplasma hyopneumoniae, swine enzootic pneumonia, transmembrane 
proteins. 
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Introduction 
Porcine enzootic pneumonia, caused by M. hyopneumoniae, is a chronic respiratory 
disease  affecting swine populations worldwide (Thacker, 2006).Vaccination is the most 
effective way to control EP, combined with hygiene and management procedures (Lin et al., 
2003; Conceição et al., 2006; Maes et al., 2008). However, the vaccines currently used 
provide only partial protection (Thacker et al., 2000). These vaccines consist of inactivated 
whole-cell preparations (bacterins), and the vaccine is expensive (Chen et al., 2001), as in 
vitro growth of M. hyopneumoniae requires a rich medium and is a time consuming process 
(Thacker, 2006). Besides, more efficient and cheaper vaccines and improved diagnostic 
assays could contribute to the control of EP.   
Some studies have tried to identify and characterize antigens from M. hyopneumoniae 
with vaccine and diagnostic potential (Castro et al., 2006; Chen et al., 2006; Conceição et al., 
2006; Meens et al., 2009; Yang et al., 2005). However, only few recombinant antigens have 
been characterized so far. Bioinformatics tools can be used for predicting potential antigens in 
silico, narrowing down the universe to be tested. In addition, this approach has the advantage 
of revealing proteins independently of their abundance and without the need to grow the 
microorganism in vitro (Adu-Bobie, et al., 2003).The aim of this study was to identify, clone 
and characterize transmembrane proteins, targets for many pharmaceuticals in use today, from 
M. hyopneumoniae which may be useful in immunodiagnosis and/or vaccination against EP. 
 
Materials and methods 
Strains and growth conditions 
M. hyopneumoniae strain 7448 was gently provided by Centro Nacional de Pesquisa 
em Suínos e Aves (CNPSA – Embrapa, Concórdia, SC). Genomic DNA was extracted with 
GFX genomic blood DNA purification kit (GE Healthcare). Escherichia coli TOP 10 
(Invitrogen) and E. coli BL21 (DE3) RIL (Stratagene) were grown at 37 ºC in Luria Bertani 
(LB) medium supplemented with kanamycin (100 µg.ml
-1
), as required.  
In silico selection of open reading frame and primer design 
 One hundred and thirty six open reading frame (ORF) belonging to the group of 
transmembrane proteins of M. hyopneumoniae strain 7448 (GenBank accession number 
NC007332), previously characterized (http://www.genesul.lncc.br), were analyzed by 
bioinformatics software. To determine the signal peptide, the SignalP software was used. 
Vector NTI 10 (Invitrogen) was used to identify sequences with predominantly hydrophilic 
regions, and with no more than three TGA tryptophan codons. Primers were designed to 
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amplify the selected sequences. The forward primer included the sequence CACC for 
directional cloning into expression vector pET200/D-TOPO® (Invitrogen). The primers used 
in this study are shown in Table 1. 
Amplification and cloning of coding sequences 
The selected sequences were amplified by PCR using Mastercycle Gradient 
(Eppendorf) thermocycler, with the following program: 95 ºC for 7 min followed by 30 cycles 
of 95 ºC for 1 min, 55 ºC for 1 min and 68 ºC for 1 min, with a final extension of 68 ºC for 7 
min. The reactions were performed in a final volume of 25 µl, containing 50 ng of template 
DNA, 10 pmol of each primer, 1 × enhancer, 1 × enzyme buffer, 2.5 mM MgCl2, 0.2 mM of 
dNTPs and 2.5 units of Platinum Pfx DNA Polymerase (Invitrogen). Sequences that contained 
TGA codons were submitted to site-directed mutagenesis according to Simionatto et al. 
(2009). PCR products were cloned in Champion pET200/D-TOPO® (Invitrogen) expression 
vector following the manufacturer’s instructions. E. coli Top 10 competent cells were 
transformed by electroporation with the ligation product, as described by Sambrook & Russell 
(2001). The recombinant clones were selected and plasmid DNA was extracted and 
characterized by digestion with restriction enzymes and DNA sequencing using a MegaBACE 
500 DNA sequencer and the Dynamic ET-terminator technology (GE Healthcare). 
Expression, solubility testing and purification of recombinant proteins 
Recombinant plasmids were transformed into E. coli BL21 (DE3) Ril.  The resulting 
colonies were used to inoculate 10 ml of LB broth supplemented with 100 µg.ml
-1
 of 
kanamycin and grown in shaker (37 ºC, 250 rpm). When the log phase was reached, 
expression was induced with 0.5 mM isopropyl-β-D-thiogalactopyranoside (IPTG) for 3 h. 
Two fractions of 500 µl, one collected before and another after induction, were centrifuged at 
14,000 × g for 1 min. The sediment was used to verify expression of recombinant proteins by 
12% SDS-PAGE. The recombinant protein solubility test was performed using 2 ml of the 
sample induced and subjected to centrifugation of 14,000 × g for 5 min. A volume of 500 µl 
of 1 × phosphate buffered saline (PBS) was used to suspend the pellet and the cells were lysed 
by six cycles of sonication (15 s, 20 kHz).The soluble and insoluble fractions were separated 
by centrifugation at 10,000 × g for 5 min at 4 ºC. Both fractions were processed and subjected 
to electrophoresis in 12% SDS-PAGE.  
A clone of each recombinant plasmid was used to inoculate 15 ml of LB containing 
100 µg.ml
-1
 of kanamycin and grown overnight in shaker (37 ºC, 250 rpm). This culture was 
used to inoculate 500 ml of LB broth supplemented with kanamycin under the same 
conditions described above. After 3 h of induction, the culture was subjected to centrifugation 
Experimental studies 
 
99 
 
 at 10,000 × g for 20 min at 4 ºC, the supernatant discarded and the pellet subjected to two 
successive washes in 60 ml of PBS and centrifuged under the same conditions. Then, it was 
suspended in 60 ml of lysis buffer (8 M urea, 20 mM Na2HPO4, 0.5 M NaCl, 5 mM 
Imidazole). The cells were lysed by six cycles of sonication (15 s, 20 kHz) and submitted to 
orbital shaking of 60 rpm for 16 h at 4 ºC. After this, the lysate was centrifuged again at 
10,000 × g for 1 h at 4 ºC, the supernatant containing the protein was collected, filtered 
through a membrane filter of 0.8 µm (Millipore) and used for purification. The purification of 
recombinant proteins was done by affinity chromatography using HisTrap™ HP 1 ml 
columns prepacked with precharged Ni Sepharose™ using the ÄKTAprime™ automated 
liquid chromatography system (GE Healthcare). Fractions containing recombinant proteins 
were identified by SDS-PAGE and quantified by BCA™ Protein Assay (Pierce) following the 
manufacturer's instructions. 
Inoculation of mice with recombinant proteins 
Animal experiments were carried out according to the guidelines of the Ethics 
Committee in Animal Experimentation of the Federal University of Pelotas. Female and male 
BALB/c mice aged 7 to 8 weeks were used in the experiments. Eight groups of mice with five 
animals each, were inoculated intramuscularly (IM) with 50 µg of recombinant proteins, one 
per group in 15% aluminum hydroxide adjuvant on day zero. A group inoculated with a 
commercial bacterin was used as positive control and another group received 100 µL of PBS 
with the same adjuvant, as negative control. Each animal was boosted with the same dose 21 
days after the first inoculation. Blood samples were collected from the retro-orbital sinus at 0, 
21, 42, 63, 84, and 105 days post inoculation (DPI). The sera were processed and stored at -20 
ºC until tested. At day 105, mice were euthanized.  
Evaluation of immune response  
ELISA using recombinant proteins as antigen 
Specific antibodies against recombinant proteins in sera from immunized mice were 
assayed by indirect ELISA. Microtiter plates were coated with 100 µL of each recombinant 
protein at a concentration ranging from 5 to 50 ng/well in 0.1 M sodium carbonate buffer (pH 
9.6),  at 4 ºC overnight. The plates were washed three times with PBS (pH 7.4) with 0.05% 
(v/v) Tween 20 (PBST) and incubated with 200 µL of 5% blocking buffer at 37 ºC for 2 h. 
After washing with PBST, wells were incubated with mice sera, in triplicate, of each 
individual animal, diluted 1:50 in blocking buffer, at 37 ºC for 1 h. After washing with PBST, 
goat anti-mouse peroxidase conjugate (Sigma Aldrich) diluted 1:6000 was added and the plate 
was incubated at 37 ºC for 1 h. The reactions were developed with o-
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phenylenediaminedihydrochloride (Sigma) and hydrogen peroxide, after PBST washes. The 
color reaction was allowed to develop for 15 min before being stopped with 50 µl of sulfuric 
acid 1 N. Absorbance was determined at 492 nm with a microplate reader (Multiskan 
MCC/340, Titertek Instruments). Mean values were calculated from sera samples assayed in 
triplicate. 
ELISA using extract of M. hyopneumoniae 7448 strain as antigen 
An ELISA was performed with sera from mice immunized with recombinant proteins 
to verify if the antibodies induced by these antigens were able to recognize M. 
hyopneumoniae derived proteins. For this, 1 µg of crude extract of M. hyopneumoniae strain 
7448, dissolved in 0.1 M sodium carbonate buffer (pH 9.6), was added to each well of 
microtiter plates. The plates were incubated overnight at 4 ºC, then incubated at -70 ºC for 2 h 
and thawed at room temperature for 30 min. Then, the same procedure described above was 
used, except that sera from animals of each group were pooled before testing. Mean values 
were calculated from pooled sera samples assayed in triplicate. 
Western blot with M. hyopneumoniae derived proteins 
In order to evaluate the ability of antibodies from mice immunized with recombinant 
proteins to recognize derived proteins from Mycoplasma sp., lysates of M. hyorhinis, M. 
hyopneumoniae 7448, 7422 and J
T 
strains, were used in Western blot analysis. Samples were 
solubilized in sample buffer (62.5 mM Tris-HCl (pH 6.8), 10% glycerol, 5% 2-
mercaptoethanol, 2% SDS) and separated by 10% SDS-PAGE. Mycoplasma derived proteins 
were transferred onto nitrocellulose membranes (GE Healthcare) using a mini transblotter, 
following the manufacturer’s instructions (Bio-Rad). The membrane was blocked overnight at 
4 ºC in 5% nonfat dried milk-PBST and probed with polled sera from each group of mice 
(diluted 1:50 in blocking buffer). Specific antibodies were detected with goat anti-mouse 
peroxidase conjugate. Immunoreactive protein bands were detected using 3,3`-
diaminobenzidinetetrahydrochloride (DAB) and 0.015% (v/v) hydrogen peroxide in PBS. 
Sera from mice immunized with PBS and bacterin were used as negative and positive 
controls, respectively. 
Antigenicity of the recombinant antigens 
Serum samples from SPF pigs and from naturally infected pigs (from a commercial 
herd with clinical signs and pathological lesions compatible with EP) were used to evaluate 
the reactivity of recombinant antigens with antibodies produced during infection. The sera 
were tested by Western blot and ELISA. 
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Western blot 
Purified recombinant proteins were solubilized in sample buffer and submitted to 12% 
SDS-PAGE. Proteins were transferred onto nitrocellulose membranes (GE Healthcare) using 
a mini transblotter (Bio-Rad) following the manufacturer’s instructions. Membranes were 
incubated in 5% blocking buffer overnight at 4 ºC. After washing with PBST, membranes 
were incubated individually with adsorbed sera (diluted 1:100 in blocking buffer) from SPF 
(1), pool of 3 immunized pigs, or 10 naturally infected pigs, for 2 h at 37 ºC. To reduce the 
background, the sera were previously adsorbed in E. coli extract. Membranes were washed 
with PBST (3 × 5 min per wash) and incubated for 1 h at 37 ºC with rabbit anti-pig IgG 
peroxidase conjugate, diluted 1:6000 in blocking buffer. Membranes were washed in PBST (3 
× 5 min per wash). Immunoreactive protein bands were detected using 3,3`-
diaminobenzidinetetrahydrochloride (DAB) and 0.015% (v/v) hydrogen peroxide in PBS. 
ELISA 
To assess the antigenicity of recombinant proteins by ELISA, porcine sera from 
animals naturally infected (n=22) and SPF (n=5) were used. Sera from naturally infected pigs 
had antibody titers checked by cell ELISA. Microtiter plate were coated with 5 to 50 ng of 
each recombinant protein in 0.1 M sodium carbonate buffer (pH 9.6), at 4 ºC overnight. The 
plates were washed three times with PBST, and incubated with 200 µL of 5% blocking buffer, 
at 37 ºC for 2 h. After washing with PBST, wells were incubated with swine sera, in triplicate, 
diluted 1:100 in blocking buffer, at 37 ºC for 2 h. After washing with PBST, wells were 
incubated with rabbit anti-pig IgG peroxidase conjugate, diluted 1:6000, at 37 ºC for 1 h. The 
reactions were developed with o-phenylenediaminedihydrochloride (Sigma) and hydrogen 
peroxide, after PBST washes. The color reaction was allowed to develop for 15 min and 
stopped with the addition of 50 µL of 1 N H2SO4. Absorbance was determined at 492 nm with 
a microplate reader. Mean values were calculated from sera samples assayed in triplicate. 
MHC-I antigenic peptide processing prediction of characterized recombinant antigens 
Peptides were predicted using MAPPP (Hakenberg et al., 2003) with the SYFPEITHY 
matrix (available at http://www.mpiib-berlin.mpg.de/MAPPP/expertquery.html) which 
combines existing prediction tools for proteasomal processing and MHC class I anchoring. 
We considered the epitopes when the MHC, from human (HLA) and mouse (H2), bound 
epitope evolved from a proteasomal cleaved fragment with exactly the same size, considering 
all nonamers with potential binding for any of the alleles available. For each nonamer and 
allele, the program produced a binding score that corresponded to the estimate of half-time of 
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disassociation for a given peptide. That score was expressed as a percentage of the maximum 
score possible for a given allele. 
Statistical analysis 
The Student’s t-test was used to determine significant differences (p<0.05) in ELISA 
with recombinant proteins using pig sera and cell ELISA of mice immunized with 
recombinant proteins. GraphPad Prism 4 software systems (GraphPad Software) were used to 
perform the statistical analyses. 
 
Results 
Selection of ORFs 
The following criteria were used for selecting among ORFs encoding predicted 
transmembrane proteins to be cloned and expressed in E. coli: proteins previously 
characterized as virulence factors or orthologous to virulence factors characterized in other 
pathogens; hydrophobicity properties of the protein and with no more than three trypthophan 
(TGA) codons. Preference was given to hydrophilic regions without TGA codons. A total of 
17 ORFs belonging to the group of transmembrane proteins of M. hyopneumoniae met these 
criteria and were selected. One of these had two selected regions, C and N-terminal. A total of 
18 fragments were selected and primers were designed (Table 1). 
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Table 1. Identification of selected ORFs and primer sequences. 
*CACC: Sequence of nucleotides added for directional cloning in the vector Champion pET 
200/D-TOPO
® 
(Invitrogen). 
** Pair of primers used for mutation from TGA to TGG codon. 
 
Amplification, cloning and characterization of genes 
All 18 selected fragments were amplified by PCR. Two fragments that had TGA 
tryptophan codons were submitted to site-directed mutagenesis and had the TGA replaced by 
 
Nº 
 
Annotation 
Selected 
Fragment 
(aa) 
 
Primer sequences 
1 MHP0019 238 - 665 For* CACCGGATCCGGCAAATTCAAAACTGGAC 
RevGGGAAGCTTTCACAAAACCCCAATCATTTTC 
2 MHP0020 16 - 298 For CACCGGATCCATTTTTAAAAAAATTAATCTTGTA 
Rev GGGAAGCTTTCATATTGAAATTGAATCTAATT 
3 MHP0241 20 - 195 
 
ForCACCGGATCCTTTCTTGCTTTTTTGACTT 
Rev CCCAAGCTTTCACTCAAGTTGAGCTTTTTTATC 
4 MHP0248 248 - 748 For CACCGGATCCCTAGGACAGTTTGCAATAATTATTGT 
RevCCCAAGCTTTCATTTATCTTTTTTATCATCAATAATTTC 
     For mut** GGATTTTGgGAATGgTTTTGgGGCAAATTA 
RevmutTTTGCCcCAAAAcCATTCcCAAAATCCTTG 
5 MHP0265 123 - 311 For CACCGGATCCTATTTAGTAAAACCGACTGTTT 
Rev CCCAAGCTTTCACTTTGGCAAATGCGAAA 
6 MHP0328 1 - 172 For CACCGGATCCATGACCAAATTTGCAAAA 
Rev CCCAAGCTTTCAGCTAGTAACATGTTCTTTCCA 
7 MHP0332 56 - 264 ForCACCGGATCCTATGCTTCAAATTTTAGT 
Rev CCCAAGCTTTCACTTATTAGTAGATC 
8 MHP0344 1 - 166 For CACCGGATCCATGAAAATAAAAAACAAA 
Rev CCCAAGCTTTCAAGGGAATGGAGTACC 
9 MHP0383 1 - 257 ForCACCGGATCCATGATTCAAATTCGTAATGTT 
Rev CCCAAGCTTTCATATTTTTTTGCTAATATCAGC 
10 MHP0414 N 904 -1199 For 
CACCGGATCCTTCAATAGAAAAGAATATTATACTATTC 
RevGGGAAGCTTTCATTTATTAACTAAATTATGAAA 
11 MHP0414 C 67-284 For CACCGGATCCATAAACAACCCAAATATTTATTC 
Rev GGGAAGCTTTTAACTATTATACCTTTTAATTTTCC 
12 MHP0443 31 - 512 ForCACCGGGTACCGATTGATTTTGTCTTTTTTG 
Rev CCCAAGCTTTCAGATTCTACCATTAATCTTT 
13 MHP0480 258 - 524 For CACCGGATCCAATGACTGGATCAAAAACTA 
Rev CCCAAGCTTTCATGCTTTATTATTATCGATC 
14 MHP0487 2 - 284 ForCACCGGATCCGATAAAAAAAGTTCTTTTCTTTT 
Rev CCCAAGCTTTCAAAAAACTCTTGATTTTACGAT 
15 MHP0489 576 - 744 For CACCGGATCCCAGCAAACTTATAATTCTC 
Rev CCCAAGCTTTCAGGAATAATCAAGAACGA 
16 MHP0544 31- 386 For CACCGGATCCATTAAATCAGTTGATATTAATTCTTTTT 
RevGGGAAGCTTTCAGCATGAATTTATTTTTTTTATTA 
17 MHP0596 110 - 379 For CACCGGATCCCTTAGCCAAAATCCACTAC 
Rev CCCAAGCTTTCAATTTTCGTTTTTATC 
18 MHP0643 131 - 345 ForCACCGGATCCTTTTTTATCGGTTTTTTTTAT 
Rev GGGAAGCTTTCAGTTAATCGTTACAATATTTG 
     For mutCCAGTCTGgAAAGAGAATAATT 
    RevmutATTCTCTTTcCAGACTGGAAT 
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TGG codons. The PCR amplified sequences were cloned into Champion pET200/D-TOPO® 
(Invitrogen) and transformed into E.coli TOP10 electro competent cells. Out of the 18 
amplicons, 16 were successfully cloned and characterized (Table 2).  
Expression and purification  
Clones characterized by restriction enzyme showing the insert of the expected size 
were subjected to transformation by heat shock in the expression strain E. coli BL21 (DE3) 
RIL. Before being expressed in large scale, the recombinant proteins were assessed in small 
volume growth for their expression and solubility. All the expressed proteins were insoluble 
and had to be solubilized with a denaturing agent containing urea. As the expression vector 
used (pET200/D-TOPO) allows the fusion of 6 histidine residues in the N-terminal of 
recombinant proteins, they were purified by affinity chromatography. Among the 16 clones, 
11 recombinant proteins were expressed and six were successfully purified in concentrations 
suitable for immunizations and other tests (Fig. 1). The remaining five recombinant proteins 
were expressed in low levels and purification was not successful. The yield of recombinant 
proteins ranged from 4.4 to 6.6 mg l
-1 
of culture growth. 
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Table 2. Identification of genes that code for proteins selected, features, size and results. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a: ICEF-II: integrative conjugal element – II; b: React with one of ten sera evaluated; c: React with seven of ten sera evaluated.
 
Annotation 
 
Features 
Molecular 
Mass (kDa) 
 
Cloning 
 
Expression 
 
Purification 
Mice 
immunization 
Antigenicity with pig sera 
(Western blot) 
MHP0019 
 
ABC transporter 50 Yes No No No - 
MHP0020 
 
ABC transporter 35 Yes Yes No No - 
MHP0241 
 
Translocase 22 Yes Yes No No - 
MHP0248 
 
Hypothetical protein 60 Yes No No No - 
MHP0265 
 
ABC transporter 23 Yes No No No - 
MHP0328 
 
Hypothetical protein 21 Yes Yes Yes Yes +b 
MHP0332 
 
Serine protease 25 Yes Yes Yes Yes + 
MHP0344 
 
Hypothetical protein 19 Yes No No No - 
MHP0383 
 
ABC transporter 29 Yes No No No - 
   MHP0414 C 
 
Putative ICEF-IIa 31 Yes Yes Yes Yes - 
   MHP0414 N 
 
Putative ICEF-II 26 Yes Yes Yes No +++c 
MHP0443 Hypothetical protein 56 
 
No No No No - 
MHP0480 Hypothetical protein 31 Yes Yes Yes Yes - 
 
MHP0487 
  
Putative Mg transport   
 
32 
 
No 
 
No 
 
No 
 
No 
 
- 
 
MHP0489 
 
 
Hypothetical protein 
 
20 
 
Yes 
 
Yes 
 
 
Yes 
 
Yes 
 
- 
MHP0544 Hypothetical protein 41 Yes Yes No No - 
 
MHP0596 
 
 
Hypothetical protein 
 
31 
 
Yes 
 
Yes 
 
Yes 
 
Yes 
 
+++ 
MHP0643 Hemolysin C 26 Yes Yes No No - 
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Figure 1. Twelve percent SDS-PAGE of six recombinant proteins puriﬁed by Ni-Sepharose 
afﬁnity chromatography. Lane 1, MHP0332 (25 kDa); Lane 2, MHP0480 (31 kDa); Lane 3, 
MHP0328 (21 kDa); Lane 4, MHP0489 (20 kDa); Lane 5, MHP0596 (31 kDa); Lane 6, 
MHP0414 C (31 kDa). 
 
Systemic humoral immune response 
The ability of recombinant proteins, produced from ORF, to stimulate specific 
antibodies after immunization of mice was determined by an indirect ELISA. Groups of 
animals were identified as A: negative control (saline + adjuvant), B: MHP0332, C: 
MHP0414 C, D: MHP0480, E: MHP0489, F: MHP0596, G: MHP0328, and group H: animals 
inoculated with bacterin. All recombinant proteins were able to induce a specific immune 
response statistically significant when compared with the control group. The highest immune 
response was induced by the protein produced from ORF MHP0328, while the MHP0596 
induced the lowest immune response among all proteins tested. Figure 2 shows the responses 
of all proteins up to the day 84 after immunization. 
 
 
 
 
 
 
 
  
Experimental studies 
 
107 
 
 
 
 
 
 
 
Figure 2. Antibody responses of mice immunized with recombinant proteins determined by 
indirect ELISA. Reactivity of the serum diluted 1:50, in triplicate. Goat anti-mouse 
peroxidase conjugate (diluted 1:4000) was used as the secondary antibody. The data represent 
the mean OD492. Vertical lines represent standard deviation. 
 
Sera from inoculated mice were also evaluated by ELISA against the whole cell 
extract of M. hyopneumoniae strain 7448. Proteins derived from ORFs MHP0480 and 
MHP0328 showed statistically significant differences in absorbance values when sera 
collected on day 84 after immunization was compared to the pre-immune serum (Fig. 3).  
Western blot analysis was carried out with mouse sera raised against six recombinant 
proteins and revealed that antibodies were able to recognize mycoplasma derived proteins. 
Five recombinant proteins induced antibodies that reacted with derived proteins from M. 
hyopneumoniae 7448, 7422, J
T 
strains and M. hyorhinis. The MHP0480 recombinant protein 
induced antibodies that appear not to cross-react with M. hyorhinis (data not shown), a 
common secondary invader in swine pneumonia. Sera from mice inoculated with saline did 
not recognized mycoplasma proteins, while sera from mice inoculated with bacterin 
recognized several mycoplasma proteins. 
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Figure 3. ELISA reactions using extract of M. hyopneumoniae as antigen. Detection of the 
antibodies in sera from mice immunized with recombinant proteins (diluted 1:20). Goat anti-
mouse peroxidase conjugate (diluted 1:4000) was used as the secondary antibody. PI, pre-
inoculation mouse sera; DPI, sera of mice obtained 105 days post-inoculation; Sal and Bact, 
are the negative group inoculated with PBS and positive group immunized with bacterin, 
respectively. The data represent the mean OD492 of sera (105 DPI) from immunized mice. 
Asterisks indicate significant statistical differences (p<0.05 as compared to PI sera) using 
Student´s t-test. 
 
Antigenicity of the recombinant antigens  
Western blot analysis revealed that sera from some naturally infected animals were 
able to recognize four recombinant proteins (Table 2). Proteins produced from ORFs 
MHP0414 N (not used in the immunization tests) and MHP0596 were the most antigenic, as 
they were recognized by seven out of 10 sera tested (data not shown). 
ELISA demonstrated that sera from naturally infected pigs were able to recognize the 
recombinant proteins (Fig. 4), indicating that these proteins are expressed during infection and 
they induce a humoral immune response.  
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Figure 4. ELISA of recombinant proteins against naturally infected and SPF pig sera (diluted 
1:100). Anti-pig IgG-peroxidase conjugate (diluted 1:6000) was used as the secondary 
antibody. All recombinant proteins showed significant statistical difference (P0.05 as 
compared to SPF sera). The data represent the analyses of 5 SPF and 22 naturally infected pig 
sera. Absorbance values were statistically analyzed with a paired t-test using GraphPad Prism 
4.0 software (P<0,05). Boxes represent the interquartile range in the middle 50% of 
absorbance values. Whiskers represent the minimum and maximum values.  
 
MHC-I antigenic peptide processing prediction of characterized recombinant antigens 
We considered the epitopes when the MHC bound epitope evolved from a proteasomal 
cleaved fragment with exactly the same size. All recombinant proteins evaluated contain at 
least one epitope that have the greatest probability to be processed and finally presented on 
the cell surface. It is expected that those peptides which have higher affinity for HLA and H2 
molecules are more likely to be recognized by receptors of specific T cells.The peptides 
representing predicted dominant MHC class I epitopes from recombinant antigens are shown 
in Table 3. 
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Table 3. MHC bound epitope evolved from a proteasomal cleaved fragment with exactly the 
same size from characterized recombinant antigens of M. hyopneumoniae. 
Annotation Epitope Epitope 
Position 
MHC 
type 
Cleavage 
Probability 
MHC 
Binding Score 
 
MHP0328 
 
TMEDFANKL 
 
156 
 
HLA_A_0201 
 
0.9997 
 
0.6111 
MHP0332 
IREPFAKQL 10 HLA_B_2705 1.0000 0.6486 
QFLDNYYYYL 127 H2_Db 1.0000 0.7273 
QFLDNYYYYL 127 H2_Kd 1.0000 0.7143 
MHP0414 C 
KRNQNIFDQL 47 H2_Db 1.0000 0.7273 
QLPKKIINL 55 HLA_A_0201 0.9719 0.6944 
SNLPNIKDL 149 H2_Db 0.9966 0.6857 
 
MHP0480 
LLDFSLNQL 13 HLA_A_0201 0.9718 0.7222 
NLSSSEIINL 73 HLA_A_0201 1.0000 0.7059 
 
 
MHP0489 
 
SYYPYFDSRA 54 H2_Kd 1.0000 0.7143 
RYQFGQGHKL 66 H2_Kd 0.9847 0.8214 
CLKYRAFLL 93 HLA_B8 1.0000 0.8140 
KRNLSIDYL 115 HLA_B_2705 0.9990 0.7297 
YLLKIINYEV 122 HLA_A_0201 1.0000 0.7941 
MHP0596 
LSQNPLPEL 0 H2_Ld 1.0000 0.7097 
ILSIITKTKL 95 HLA_A_0201 1.0000 0.7059 
SYNKHKMQQL 208 H2_Kd 1.0000 0.8571 
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Discussion 
Production of recombinant proteins of M. hyopneumoniae in E.coli has been suggested 
as an alternative not only for vaccine production, but also for diagnostic tests of EP 
(Simionatto et al., 2010). Vaccination has been an important preventive tool in controlling 
infection by M. hyopneumoniae (Reynolds et al., 2009). However, commercial vaccines 
confer only partial protection (Haesebrouck et al., 2004). The sequencing of four strains of M. 
hyopneumoniae (Liu et al., 2011; Minion et al., 2004, Vasconcelos et al., 2005) has allowed 
the use of a genomic approach in the production of recombinant subunit vaccines, named 
reverse vaccinology (Rappuoli, 2000). This approach may contribute for the development of 
new and more effective vaccines against EP and in identification of proteins that are 
expressed during infection and can thus be used in diagnostic tests. 
In this study, recombinant antigens belonging to the group of transmembrane proteins 
of M. hyopneumoniae were evaluated as candidates for vaccine and for use in sero diagnosis 
of EP. Transmembrane proteins play critical roles in cellular metabolism, participating in 
processes such as ion transport, nutrient uptake, signal transduction, and intercellular 
communication. As evidence of the essential functions of these proteins, more than half of all 
drug targets have been shown to be transmembrane proteins, and the analysis of the 
interactions of transmembrane proteins and their ligands is one of the most promising avenues 
for the discovery of new drug candidates as well vaccine targets (Yoshino et al., 2010; 
Janulczyk and Rasmussen, 2001). 
The proteins evaluated in this study were first assessed through bioinformatics 
software to confirm their location, presence of potential immunogenic epitopes and to 
evaluate the number of TGA codons, which in M. hyopneumoniae code for tryptophan, but in 
other organisms are stop codons. The directional cloning strategy used was effective, allowing 
the cloning of all selected fragments, despite the fact that the genome of M. hyopneumoniae is 
rich in AT (72%) (Vasconcelos et al., 2005). The recombinant proteins were expressed in 
insoluble form, although hydrophilic regions of the proteins were predominantly selected. 
This fact can be justified because transmembrane proteins are generally expressed at low 
levels and have hydrophobic domains. There are considerable challenges to be overcome for 
the stable expression of transmembrane proteins, as many of them have cytotoxic effects 
when overexpressed (Wagner et al., 2007), leading to formation of inclusion bodies (Georgiou 
and Segatori, 2005).  
Six recombinant proteins were purified in sufficient amounts for further analyses. 
Immunization of mice with the recombinant proteins revealed that all of them induced a 
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specific humoral immune response. The hypothetical protein, produced from  ORF MHP0328 
induced the highest humoral immune response, assessed by both, ELISA and cell ELISA, 
suggesting that this antigen may be a candidate for vaccine formulations. None of the 
recombinant proteins evaluated in this study showed response when reacted with the serum of 
the group of animals inoculated with the commercial vaccine (data not shown). This indicates 
that these antigens are not expressed by the vaccine strain. The absence of immunogenic 
antigens in the vaccine strains could be the explanation for the limited efficiency of 
commercial bacterins. 
The mechanisms responsible for immune protection against M. hyopneumoniae are 
complex and not well understood yet (Reynolds et al., 2009). Thacker et al. (2000) suggested 
that eradication of the pathogen is dependent on the presence of antibodies in the serum and 
on cell-mediated immunity during infection. Therefore, promising antigens for formulation of 
vaccines should induce both types of response. In this study, all antigens were able to induce a 
humoral immune response when evaluated in mice. Although the cellular immune response 
induced by these recombinant antigens was not evaluated, they have one or more epitopes 
binding to MHC-I. In silico T-cell epitope mapping using computational models has been 
used in cancer immunity (Depilet al., 2007), autoimmunity (Honeyman et al., 1998), 
infectious diseases (Brusic et al., 2001), allergy (De Lalla et al., 1999) and is currently 
emerging as a novel approach for the study of genome-based peptide vaccines (De Groot, 
2006). 
ELISA demonstrated that all proteins showed a significant reaction with sera from 
naturally infected pigs. The recognition of the recombinant proteins by serum from pigs 
naturally infected indicates that these proteins are expressed during infection, suggesting that 
they have potential to be used in serological diagnostic tests. However, when these proteins 
were tested by Western blot, four were recognized by antibodies in the sera, two of them, 
MHP0596 (hypothetical protein) and MHP0414 N (putative ICEF-II), were recognized by 
seven out of ten sera evaluated. From all recombinant proteins evaluated in this study, only 
the MHP0480 did not react with M. hyorhinis, a common secondary invader found in the 
respiratory tract of pigs, suggesting that it could be used for immunodiagnosis of EP. 
Production of experimental recombinant vaccines against EP has been pursued by 
many scientists. Some of these vaccine candidates have shown promising results (Chen et al., 
2003; Fagan et al., 1996; Okamba et al., 2010; Shimoji et al., 2003). However, just two 
antigens have been evaluated, and they were able to confer only partial protection for pigs. 
This can be attributed to the fact that they were formulated with a single antigen. A multiple 
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antigen vaccine has the potential to offer more adequate protection (Chen et al., 2008; 
Okamba et al., 2010).  
In the present study it was demonstrated that six transmembrane proteins of M. 
hyopneumoniae, not previously characterized, are immunogenic and expressed during 
infection, suggesting that these antigens have potential to be used as vaccine against EP, as 
well as in diagnostic tests. Although the immune response of mice cannot be extrapolated to 
other species and no direct correlation has been found between antibody concentration and 
protection against M. hyopneumoniae challenge (Djordjevic et al., 1997), the results warrant 
further investigation in challenge experiments in pigs.  
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General Discussion 
 
M. hyopneumoniae is the causal agent of enzootic pneumonia, a contagious pulmonary 
disease of swine characterised by a dry, non-productive cough, reduced growth rate and poor 
feed conversion efficiency, that represents a costly problem for the pig industry worldwide 
(Thacker and Minion, 2010). Factors such as management practices, housing conditions, 
secondary infections and the use of antimicrobials and commercial bacterin-based vaccines 
can influence the severity of mycoplasmal respiratory disease in pig herds (Maes et al., 2008).  
In addition, the virulence status of M. hyopneumoniae isolates may also affect the 
clinical pattern of infection, and thus the protective efficacy of vaccination may vary 
depending on the virulence of the strain causing infection (Vicca et al., 2003; Villarreal et al., 
2011). Notwithstanding the efforts and control strategies adopted to rear high health pig herds, 
M. hyopneumoniae continues to be a widely spread organism in pig populations, which 
renders eradication of this respiratory disease a very difficult and frustrating task.  
In the present thesis, the immune responses induced by a commercially available 
adjuvanted bacterin against M. hyopneumoniae were investigated, and a new vaccine based on 
recombinant proteins of M. hyopneumoniae was developed. 
 
Immune response induced by a commercial bacterin in pigs 
The currently used vaccines consist of adjuvanted, inactivated, whole-cell preparations 
and have been proven extensively to be effective in reducing the clinical symptoms and lung 
lesions, and in decreasing performance losses associated with M. hyopneumoniae infections 
(Maes et al., 2008). However, they provide only partial protection (Villarreal et al., 2011; 
Vranckx et al., 2012), and the mechanism of protection is not yet fully understood. The study 
reported in the chapter 3.1 investigated the mechanisms by which a commercial M. 
hyopneumoniae bacterin, applied once intramuscularly in piglets of 7 days old, can induce an 
immune response against EP.  
Few information is available with regard to immune mechanisms induced by 
intramuscular vaccination with inactivated M. hyopneumoniae vaccines. The mode of action 
of the vaccine was evaluated by a number of immunological assays designed to measure local 
and systemic humoral and cellular immune responses. Understanding the immune response 
induced by the current vaccines can give better insights in the mechanisms involved in the 
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protection against EP and might be useful to develop new and more efficient strategies of 
vaccination. Immunological assays were performed on blood, bonchoalveolar lavage (BAL) 
fluid and different lymphoid tissues (lung, bronchial lymph nodes and spleen) of vaccinated 
and non-vaccinated pigs. 
In agreement with previous reports, we observed individual variations in the number 
of T cell subsets (Borghetti et al., 2006; Kick et al., 2010). In both vaccinated and non-
vaccinated pigs, the percentage of CD8
+ 
T cells increased with age of the pigs, showing that 
different T cell subsets may be present in the peripheral blood and secondary lymphoid 
tissues. In most tissues, the percentage of CD8
+ 
T cells was highest in the vaccinated group at 
58 days of age. It might be that vaccination modulates the immune response induced by a M. 
hyopneumoniae infection. CD8
+ 
T cells may modulate the inflammatory response through the 
production of IFN-γ and other cytokines, minimizing damage due to the CD4+ T (Th) cell 
mediated inflammatory responses (Jones and Simecka, 2003). This might explain why 
vaccinated animals develop less severe clinical symptoms and lung lesions than non-
vaccinated animals after challenge with M. hyopneumoniae (Meyns et al., 2006; Villarreal et 
al., 2011). 
Production of pro-inflammatory and regulatory cytokines was also determined in 
vaccinated and non-vaccinated animals. Previous studies showed that vaccination can prevent 
the pathological effects of the inflammatory cytokines through the production of IL-10 (Conti 
et al., 2003). In the vaccinated pigs of our study, a significantly higher number of IL-10 
secreting cells were detected in the bronchial lymph nodes (BLN) compared to the non-
vaccinated pigs at 58 days of age. This may also play a role in the reduction of lung tissue 
damage after infection of vaccinated animals. It is well known that IL-10 has an anti-
proliferative effect, so the induction of IL-10 secretion can reduce the macrophages influx in 
the bronchoalveolar lymphoid tissue. The reduction of macrophages in vaccinated pigs 
compared to non-vaccinated animals, after experimental infection with M. hyopneumoniae, 
has been described by Vranckx et al. (2012). 
Seo et al. (2012) suggested that a higher induction of cell-mediated immunity against 
M. hyopneumoniae was associated with a lower severity of lung lesions induced by M. 
hyopneumoniae. To better understand the effect of vaccination on cellular immune responses, 
the production of IL-12 and IFN-ɣ was evaluated. Production of IL-12 by macrophages and B 
cells has been demonstrated to be important in the induction of a Th1 immune response (Yang 
et al., 2004). Furthermore, this cytokine stimulates IFN-ɣ production and enhances CD8+ 
cytotoxicity, both contributing to maintaining the cell mediated immunity (Park and Scott, 
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2001). Indeed, vaccinated pigs showed significantly higher amounts of IL-12 in spleen, BLN 
and lung tissues. At 58 days of age, the number of IFN-ɣ secreting cells was higher in the 
lungs of the vaccinated group. Significantly higher levels of IFN-ɣ were also found in the 
BAL fluid of the vaccinated group at 30 days of age, indicating that the vaccine also induced 
a local cellular immune response. Not only a local cellular immune response, but also IgG, 
IgM and IgA specific M. hyopneumoniae antibodies were detected in the BAL fluid of 
vaccinated animals. IgA was detected at all tested time points and may play an important role 
in protection by preventing the adhesion of mycoplasmas to the ciliated epithelial cells of the 
respiratory tract (Thacker et al., 2000). 
Effects of vaccination on host immune responses induced by infection may play an 
important role in the protection against lung lesion development, as excessive levels of pro-
inflammatory cytokines like IL-1 and IL-6 were observed in BAL fluid of M. hyopneumoniae 
infected pigs (Choi et al., 2006; Thacker et al., 2000) and have been associated with tissue 
damage and even death of the host (Asai et al., 1993; Okada et al., 2000). In this study, 
highest concentrations of IL-1β and IL-6 were detected in the BAL fluid of the non-
vaccinated group. This may suggest a regulatory effect of the vaccine in the release of these 
cytokines, avoiding tissue damage in the host. 
Adjuvants may play an important role in the enhancement of the immunogenicity of 
an antigen and protection. The vaccine evaluated in the current study not only contained 
inactivated M. hyopneumoniae cells but also a complex adjuvant consisting of an acrylic acid 
polymer, carbopol 941® and squalane. Polyacrylic acid has been evaluated as adjuvant in 
veterinary vaccines against swine parvovirus (Gualandi et al., 1988), circovirus type 2 
(Hoogland et al., 2006) and Staphylococcus aureus in sheep (Tollersrud et al., 2002). These 
reports showed that carbomers such as carbopol are not harmful in mammals and stimulate a 
more robust immune response than the antigen alone. In addition, it was demonstrated that 
carbopol drives an adaptive immune response with strong Th1-biased antibody production 
and T cell responses characterized by high levels of Th1 and Th2 cytokines when evaluated in 
mice (Krashias et al., 2010). Moreover, squalane was found to cause significant local immune 
stimulation and recruit and increase antigen uptake by dendritic cells that participate in 
antigen transport to draining lymph nodes (Calabro et al., 2011). 
Very recently a study showed that vaccination pigs of less than one week of age with 
this commercial bacterin is effective in reducing lung lesions and performance losses due to 
M. hyopneumoniae infection (Wilson et al., 2012). However, further studies are still required 
to elucidate the mechanisms involved in induction of local antibodies and cellular immunity 
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after parenteral administration of this inactivated vaccine and its interaction with the 
protection against M. hyopneumoniae infection. 
 
Development of new strategies for control of EP 
The current control measures, including vaccination with the commercial vaccines, 
limit the economic damage. However, they provide only a partial protection, and do not 
constitute a sustainable control of EP (Thacker et al., 2000). 
One of the disadvantages of bacterins is that they contain multiple antigens, and that 
some of these may even inhibit a protective immune response (Haesebrouck et al., 2004). The 
current bacterins are based on in vitro grown strains and do not contain antigens that are only 
expressed in vivo. Madsen et al. (2008) indeed observed differential protein expression 
between in vivo and in vitro grown strains. Furthermore, differences between circulating 
strains and strains included in commercial vaccines have been described which also might 
result in a lower efficacy of vaccination.  
All licensed vaccines against EP should be applied parenterally, a route of 
immunization which, in general, is most effective for inducing systemic immune responses. 
However, as many respiratory pathogens, M. hyopneumoniae colonises mucosal surfaces, and 
the efficacy of the vaccines against this organism may be improved if both systemic and 
mucosal immune responses are induced. Many studies have demonstrated the efficiency of 
adhesin-based vaccines in blocking the interactions between the microbial adhesins and their 
host cell receptors (Wizemann et al., 1999). M. hyopneumoniae is primarily found on the 
mucosal surface of the trachea, bronchi, and bronchioles (Blanchard et al., 1992), and the 
adherence to the ciliated epithelium is a prerequisite for initiation of the infection. The 
mechanisms of adherence are complex and not fully understood. Zhang et al (1995) identified 
the P97 protein to be a ciliary adhesin. Many other potential adhesins have also been 
described (Burnett et al., 2006; Chen et al., 1998; Seymour et al., 2011; Seymour et al., 2012). 
However, some pure adhesins as well recombinant subunit vaccines containing only one 
antigen, elicit poor immune responses and need to be administered together with an 
immunostimulative carrier molecule or vector (Wizemann et al., 1999).  
One strategy to induce mucosal immunity has been the use of bacterial enterotoxins 
such as cholera toxin (CT) from Vibrio cholerae  and the related Escherichia coli heat labile 
enterotoxin (LT), which are highly immunogenic when delivered mucosally and parenterally 
and which can acts as carriers to potentiate responses to non-related antigens (O'Hagan, 
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1998). Looking for a more complete protective response than the one generated by single 
component vaccines, a multi-component vaccine was developed. In the study presented in 
chapter 3.2, the aims were 1) to produce a recombinant chimeric protein composed of the c-
terminal portion (R1) of the adhesin P97, P42 and NrdF antigens of M. hyopneumoniae fused 
to nontoxic E. coli heat-labile enterotoxin B subunit (LTB), 2) to evaluate the capacity of this 
chimeric protein to induce a specific immune response in intramuscularly and intranasally 
vaccinated mice, as well as in intramuscularly vaccinated pigs, and 3) to compare the effect of 
the fusion and co-administration of these proteins as well as the adjuvant effect of LTB.  
Humoral and mucosal immune responses were characterized by the production of high 
levels of anti rP97R1, rP42 and rNrdF IgG in the sera and IgA antibodies in tracheobronchial 
lavage of vaccinated mice. Some of these antigens (P97R1 and NrdF) have previously been 
shown to induce specific immune responses in pigs too (Fagan et al., 2001; Okamba et al., 
2010; Shimoji et al., 2003) and the heat shock protein P42 has been considered a good 
immunogen in several studies (Chen et al., 2003; Simionatto et al., 2012). In challenge 
experiments in pigs, it was shown that induction of antibodies against P97 or P97R1 and NrdF 
reduced the severity of lung lesions caused by M. hyopneumoniae infection (Fagan et al., 
2001; Okamba et al., 2010; Shimoji et al., 2003). In addition, heat shock proteins as P42 have 
been shown to present multiple B-cell and T-cell epitopes and have also been used as an 
adjuvant to enhance cell-mediated immune responses in DNA vaccines (Chen et al., 2000). 
Foreign antigens fused to recombinant LTB might constitute useful vaccines (da Hora 
et al., 2011), if these antigens indeed can be delivered across the mucosal epithelium to the 
underlying mucosa-associated lymphoid tissue. Then, they can stimulate the mucosal immune 
system by mediating the induction of antigen-specific mucosal IgA (Kim et al., 2011). LTB 
has been shown to be a potent mucosal and systemic adjuvant towards co-administered or 
fused unrelated antigens (Liu et al., 2011a; Zhou et al., 2009). It has already been shown that 
LTB can increase both T helper type 1 and 2 (Th1 and Th2) associated cytokine responses to 
LTB-fused antigens (Zhou et al., 2009). However, E. coli heat-labile toxin (LT) has also been 
shown to have negative side effects in humans, as both native and mutant LT (mLT) used as 
adjuvants were recently associated with the development of facial nerve paralysis following 
intranasal delivery in humans (Lewis et al., 2009). It is, therefore, evident that these toxin 
adjuvants exhibit safety concerns that will likely prevent their use in nasally delivered 
vaccines for humans.   
Our results demonstrated that the presence of LTB, either co-administered or as part of 
the fusion proteins, resulted in significantly higher levels of IgG and IgA antibodies in 
General discussion 
 
125 
 
intranasally and intramuscularly immunized mice, although these levels differed between 
antigens, with higher antibody levels against the rP42. Even though no cytokine production 
was measured in the present study, it is commonly accepted that Th1 cells are preferentially 
involved in cell-mediated immunity, since they can activate B cells to produce strongly 
opsonising antibodies such as IgG2a and IgG2b in mice. In contrast, Th2 cells induce B cells 
to proliferate and produce antibodies such as IgG1 (Mosmann and Coffman, 1989). 
Intramuscular injection of the chimeric protein induced IgG1 and IgG2a. In the groups 
inoculated intranasally, significant differences were only found in the response against rP42, 
with higher levels in the group inoculated with the chimeric protein. These results indicate a 
mixed Th1 and Th2 response, mainly against the rP42.  
The chimeric protein was also able to induce specific IgG antibodies in pigs, 
demonstrating the same profile as in mice. Significant differences were detected between pre-
immunisation and post-immunisation serum antibody levels against all antigens comprising 
the chimeric protein, with higher levels of antibodies against rP42.  
In conclusion, the study in chapter 3.2 described the design and expression of a 
chimeric recombinant protein comprising three M. hyopneumoniae antigens and the adjuvant 
LTB. The chimeric protein exhibited antigenic profiles similar to those of the original 
proteins, and the antigens included induced an immune response both in mice and in pigs. To 
our knowledge, this is the first multivalent subunit recombinant vaccine synthesized as a 
single molecule for M. hyopneumoniae. This approach may result in a formulation that could 
improve the protection against EP in pigs, and facilitate the manufacturing process, since 
more than one antigen can be produced in a single process. Further research will focus on the 
protective immunity of the vaccine against experimental M. hyopneumoniae infections in 
pigs. 
Although the novel methodologies may show promising effects for the control of M. 
hyopneumoniae infections, very limited information is available on antigens of M. 
hyopneumoniae that are important for inducing protection. This is mainly due to the fact that 
the pathogen is very difficult to grow and manipulate in vitro. Antigens like P97, P97R1 and 
NrdF have been investigated in different vaccine formulations (Fagan et al., 2001; Ogawa et 
al., 2009; Okamba et al., 2010; Shimoji et al., 2003). Some of these formulations (P97 and 
Nrdf) were able to induce specific immune responses in pigs but with only limited protection 
against pulmonary lesions caused by M. hyopneumoniae infection (Fagan et al., 2001; Shimoji 
et al., 2003). So, new and more efficient strategies are required to identify antigens that might 
be useful to the development of more effective vaccines.  
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Availability of the whole genome sequences of four M. hyopneumoniae strains (Liu et 
al., 2011b; Minion et al., 2004; Vasconcelos et al., 2005) has allowed the use of reverse 
vaccinology for development of recombinant subunit vaccines (Rappuoli, 2001). This 
approach may contribute to the identification of M. hyopneumoniae antigens that might be 
important for the development of new and more effective vaccines against EP. The main 
drivers for recombinant protein-based vaccine development are development of more potent, 
safer and better characterized vaccines, providing broader protection against multiple strains 
of a bacterium (Unnikrishnan et al., 2012). 
In the study described in the chapter 3.3, recombinant antigens belonging to the group 
of transmembrane proteins of M. hyopneumoniae were evaluated as vaccine candidates. 
Transmembrane proteins play critical roles in cellular metabolism, participating in processes 
such as ion transport, nutrient uptake, signal transduction, and intercellular communication. 
The importance of these proteins is illustrated by the fact that more than half of all drug 
targets are transmembrane proteins. The analysis of the interactions of transmembrane 
proteins and their ligands is one of the most promising avenues for the discovery of new drug 
candidates as well as vaccine targets (Janulczyk and Rasmussen, 2001; Yoshino et al., 2010). 
 Six recombinant transmembrane proteins were cloned, expressed in E. coli and 
purified in sufficient amounts for use in further immunological analyses. This was not that 
easy as Mollicutes genomes have a high AT- content that reduces the expression levels of 
mycoplasmal proteins in heterologous expression systems, and there is poor intrinsic 
solubility and inherent toxicity of transmembrane proteins.  
M. hyopneumoniae is a host specific pathogen which only infects pigs. Therefore, the 
efficacy of a vaccine against EP can only be determined in pigs, making the experiment 
laborious and expensive. Immunological characterization of each antigen is important in order 
to allow selection of the most qualified antigens for clinical trials in pigs. In chapter 3.3 of the 
present thesis, the immunogenicity of each recombinant protein was determined by 
inoculating purified antigens in mice and measuring the humoral immune response. All 
recombinant proteins evaluated were immunogenic for mice. 
  In addition, none of the recombinant proteins evaluated in this study reacted with the 
serum of the group of animals inoculated with the inactivated commercial vaccine. This 
indicates that these antigens are not present in the bacterin used in the experiment. This result 
is in agreement with a previous study, where a commercial vaccine did not stimulate the 
production of serum antibodies against the C-terminal portion of the adhesion P97 either, 
suggesting that the vaccine strain did not contain the P97 adhesin (Conceição et al., 2006). 
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The absence of this antigen playing a role in colonization, could compromise the efficacy of 
the vaccine, and might be one of the reasons why commercial vaccines only induce partial 
protection. Moreover, all recombinant proteins were recognized by serum from pigs naturally 
infected, indicating that they are expressed during infection, and may have potential to be 
used in serological diagnostic tests. However, a more detailed and efficient characterization 
needs to be performed before using these proteins as a tool for immunodiagnosis of EP.  
The results of chapter 3.3 showed that six transmembrane proteins of M. 
hyopneumoniae, not previously characterized, are immunogenic and are expressed during 
infection in pigs. This suggests that these antigens may have potential to be included in a 
vaccine against EP, and that they might also be useful in diagnostic tests. Although the 
immune response of mice cannot be extrapolated to other species and no direct correlation has 
been found between serum antibody concentration and protection against M. hyopneumoniae 
challenge (Djordjevic et al., 1997), the results warrant further investigation in challenge 
experiments in pigs. 
From the studies described in this thesis, it can be concluded that intramuscular 
vaccination with an adjuvanted bacterin is able to stimulate both a systemic and a local 
immune response. Also new approaches were designed for the development of vaccines 
against EP. However, further investigations are required to obtain better insights in the role of 
the host immune response in protection on the one hand and induction of lesions on the other 
hand. It was also concluded that a multi-component vaccine is a valuable strategy to develop 
new vaccines, since many M. hyopneumoniae antigens can be obtained in a single step 
production. It is clear that more studies are necessary to better understand the stability of the 
antigens in this single molecule and to investigate their efficacy in challenge experiments in 
pigs. 
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Future Perspectives 
 
The investigated bacterin induced an immune response that might be important to 
inhibit the growth of M. hyopneumoniae and/or reduce the lesions caused by the infection. 
The immune responses of vaccinated animals following infection however are not fully 
understood, but infected pigs are unable to rapidly clear the infection. Further studies on 
bacteria–host interactions could allow selection of new protective antigens. Knowledge about 
the antigens of M. hyopneumoniae that are important for inducing protection is limited and 
more information on these antigens is necessary, as this is an essential step for the 
development of more effective vaccination and control strategies. 
The identification of new antigens has been facilitated by the fact that the genome of 
four different M. hyopneumoniae isolates has been sequenced and recombinant antigens 
evaluated. The antigens identified in this thesis were immunogenic in mice, are a first step in 
the vaccine development. They need to be tested in pigs for their possible protective 
immunity. In addition, from an immunological point of view, further research should focus on 
induction of immunity at the mucosal level. As M. hyopneumoniae organisms adhere to the 
ciliated epithelial cells of the trachea, bronchi and bronchioles, local IgA responses may be 
important for protection.  
Since even with the best antigen identification production system, vaccines might not 
reach their full potential unless they are formulated and delivered properly. Therefore, in 
addition to identifying new antigens potentially inducing mucosal immunity, research should 
also focus on other factors such as the formulation and delivery of the antigens, and the 
adjuvants leading to an appropriate and long-lasting protective immunity. For example, 
heterologous prime – boost immunisation strategies comprising priming with a DNA vaccine 
followed by boosting with recombinant proteins may be useful to enhance the immune 
response. A combination of the mentioned factors may facilitate the design and production of 
more potent and safer vaccines against EP, and vaccinesthat are also easy to administer. 
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Summary 
 
Mycoplasma hyopneumoniae (M. hyopneumoniae) is known to be the primary 
causative agent of enzootic pneumonia in pigs. This disease leads to a chronic dry cough and 
slight hyperthermia, reduces the pig’s average daily weight gain and feed conversion 
efficiency, causes low mortality but high morbidity. The infection of M. hyopneumoniae may 
also increase the susceptibility of pigs to other pathogens such as Pasteurella multocida, 
Actinobacillus pleuropneumoniae, Haemophilus parasuis, porcine reproductive and 
respiratory syndrome virus (PRRSV) and swine influenza virus, and may cause more serious 
pneumonia once complicated with infections of other respiratory pathogens. So it is a key 
pathogenic microorganism in porcine enzootic pneumonia (EP) and the porcine respiratory 
disease complex (PRDC). Both diseases represent serious health concerns worldwide in swine 
populations, and cause significant economic losses in pig production. 
M. hyopneumoniae infection can be controlled by optimizing management practices 
and housing conditions, the use of antibiotics and vaccination. Commercial vaccines consist 
of adjuvanted inactivated whole cell preparations, and are frequently used worldwide in 
countries with an intensive pig production. The currently available vaccines are beneficial 
from an economic point of view, but they do not provide a sustainable control of the disease. 
They cannot prevent colonization of M. hyopneumoniae in the respiratory tract, and do not 
significantly reduce the transmission of the pathogen. Also, little is known about the exact 
mechanisms of the partial protection they induce.  
The general aims of this thesis were to assess the mode of the action of an existing 
commercial vaccine on the one hand and to develop and evaluate new recombinant vaccines 
against M. hyopneumoniae on the other hand, looking for more effective strategies for disease 
control. For development of the recombinant vaccines, two types of antigens were considered. 
One vaccine was based on proteins known to play a role in the adhesion and that were able to 
induce a partial protection against M. hyopneumoniae infection when evaluated individually. 
The other antigens were a group of transmembrane proteins (not previously characterized). 
The identification of these novel antigens might contribute to the development of improved 
vaccines. 
The specific objectives were: 
1. To analyze the systemic as well as the local mucosal immune response induced by 
intramuscular administration of a commercial M. hyopneumoniae vaccine in pigs.
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2. To produce a recombinant chimeric protein composed of the P97R1, P42 and NrdF 
antigens of M. hyopneumoniae fused to Escherichia coli heat labile enterotoxin B 
subunit (LTB) and to evaluate the capacity of this chimeric protein to induce a specific 
immune response in mice and pigs. 
3. To identify, clone and characterize transmembrane proteins from M. hyopneumoniae 
which may be useful in vaccination against enzootic pneumonia. 
      In chapter 1, a review of the literature is given, with emphasis on vaccination 
strategies, including the use of reverse vaccinology approaches. The aims of the thesis are 
shown in chapter 2. The three experimental studies are presented in chapter 3. 
In the first study (Chapter 3.1), the mechanisms were investigated by which a 
commercial M. hyopneumoniae bacterin, applied once intramuscularly in piglets of 7 days 
old, can induce a systemic as well as a local mucosal immune response against EP. Pigs were 
euthanized and necropsied at 30, 36 and 58 days of age. Immunological assays were 
performed on blood, bonchoalveolar lavage (BAL) fluid, lung tissue, bronchial lymph nodes 
(BLN) and spleen of vaccinated and non-vaccinated pigs. Serum and BAL fluid were tested 
for the presence of antibodies by ELISA. Monomorphonuclear cells from the peripheral blood 
and tissues were isolated to quantify the T cell subsets by flow cytometry, and cytokine 
production by ELIspot and ELISA. Antibodies against M. hyopneumoniae were detected in 
serum of most vaccinated pigs at 30 days of age. M. hyopneumoniae specific IgG, IgM and 
IgA were detected in BAL fluid from vaccinated animals, but not from control animals. 
Significantly higher numbers of IL-12 secreting cells were observed in the lung at day 58 in 
the vaccinated than in the non-vaccinated group (p<0.05). The number of IL-10 secreting cells 
from BLN was also higher in the vaccinated group at day 58 (p<0.05). After restimulation in 
vitro, lymphocytes from BLN and lungs secreted significantly higher levels of IL-12 in the 
vaccinated group at day 58. These results show that the vaccine induced both systemic and 
mucosal cellular and humoral immune responses. 
In the study described in the chapter 3.2, a multi-antigen chimera with three antigens 
of M. hyopneumoniae (R1, P42 and NrdF) and the mucosal adjuvant LTB was constructed 
and its antigenic and immunogenic properties in mice and pigs were evaluated. In addition, a 
comparison between fusion and co-administration of these proteins was performed. The 
chimeric protein was constructed and expressed in E. coli. Antibodies against each subunit 
recognized the chimeric protein, showing its antigenicity. Intranasal and intramuscular 
immunization of mice with the chimeric protein significantly increased the levels of mice IgG 
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and IgA, in serum and tracheobronchial lavages, respectively. Mice immunized with chimeric 
protein, showed levels of IgG and IgA antibodies against rP42 significantly higher in both 
intramuscular and intranasal immunization (p<0.005), when compared with pre-immune 
serum. Pigs immunized with the chimeric protein developed an immune response against all 
M. hyopneumoniae antigens present in the fusion with statistically significant difference 
(p<0.05) compared to the pre-immune serum. Highest immune responses were detected in 
fused and co-administered antigens with adjuvant, proving the adjuvant effect of rLTB. 
However, better results were shown by the chimeric protein, highlighting the ability of fused 
antigens to stimulate an immune response. This multi-antigen is a promising vaccine 
candidate that may help to control M. hyopneumoniae infection. 
The availability of the whole genome sequences of four M. hyopneumoniae strains has 
allowed to use reverse vaccinology for development of recombinant subunit vaccines. This 
approach may contribute to the identification of M. hyopneumoniae antigens that might be 
important for the development of new and more effective vaccines against EP. In the third 
study (Chapter 3.3), 17 genes coding for transmembrane proteins from M. hyopneumoniae 
were cloned, among which six were successfully expressed in E. coli and their immunogenic 
and antigenic properties were investigated. All proteins were immunogenic in mice and sera 
from naturally infected pigs reacted with the recombinant proteins, suggesting that they are 
expressed during infection. These antigens may contribute to the development of new 
recombinant vaccines and diagnostic tests for EP. 
From the studies described in this thesis, it can be concluded that intramuscular 
vaccination with an adjuvanted bacterin is able to stimulate both systemic and local immune 
responses. New approaches were designed for the development of vaccines against EP. It was 
also concluded that a multi-component vaccine is a valuable approach to develop new 
vaccines, since many M. hyopneumoniae antigens can be obtained in a single step production. 
It is clear that more studies are necessary in order to better understand the stability of the 
antigens in this single molecule and their efficacy in challenge experiments in pigs will also 
have to be determined. Further investigations are required in order to obtain better insights in 
the role of the host immune response in protection on the one hand and induction of lesions on 
the other hand.  
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Samenvatting 
 
Mycoplasma hyopneumoniae (M. hyopneumoniae) is het primaire agens dat 
enzoötische pneumonie bij varkens veroorzaakt. Deze ziekte gaat gepaard met een chronische, 
droge hoest, lichte koorts, een verminderde dagelijkse groei en hogere voederconversie, hoge 
morbiditeit en meestal een lage mortaliteit. Een infectie met M. hyopneumoniae verhoogt de 
gevoeligheid van varkens voor infecties met andere pathogenen zoals Pasteurella multocida, 
Actinobacillus pleuropneumoniae, Haemophilus parasuis, porcien reproductief en respiratoir 
syndroom virus (PRRSV) en porciene influenzavirussen. Een secundaire besmetting met deze 
respiratoire pathogenen na een infectie met M. hyopneumoniae resulteert in meer 
uitgesproken symptomen en letsels. Men spreekt dan over enzoötische pneumonie (EP) of het 
porcien respiratoir ziekte complex. In dit laatste geval gaat het over infecties met M. 
hyopneumoniae in combinatie met virale pathogenen en het ziektebeeld is meer acuut in 
vergelijking met EP. Beide aandoeningen zorgen wereldwijd voor grote 
gezondheidsproblemen bij varkens en belangrijke economische verliezen voor de 
varkenssector.  
M. hyopneumoniae infecties kunnen onder controle gehouden worden door de 
bedrijfsvoering en de huisvesting op het bedrijf te optimaliseren, door het gebruik van 
antibiotica en het toepassen van vaccinatie. De huidige commerciële vaccins bevatten 
geïnactiveerde M. hyopneumoniae bacteriën en een adjuvans. Vaccinatie wordt veelvuldig en 
wereldwijd aangewend in landen met een intensieve varkenshouderij. Deze huidige vaccins 
zijn effectief vanuit economisch oogpunt, maar ze zijn niet in staat om de ziekte volledig 
onder controle te houden. De kolonisatie van M. hyopneumoniae ter hoogte van het 
ademhalingsstelsel wordt niet verhinderd en de verspreiding van het agens wordt niet 
significant verminderd door vaccinatie. Toen dit doctoraatsonderzoek opgestart werd, was het 
onvoldoende gekend welke immuunmechanismen een rol spelen bij het induceren van de 
partiële bescherming na vaccinatie met commerciële vaccins. 
De algemene doelstellingen van deze doctoraatsthesis waren enerzijds het nagaan van 
het werkingsmechanisme van een bestaand commercieel vaccin en anderzijds het ontwikkelen 
en evalueren van nieuwe vaccins op basis van recombinant aangemaakte eiwitten van M. 
hyopneumoniae, om op die manier te komen tot meer effectieve controlestrategieën. Voor de 
ontwikkeling van de nieuwe vaccins werd gebruik gemaakt van twee types antigenen. Een 
eerste vaccin was gebaseerd op drie eiwitten die een rol spelen in de adhesie van de kiem ter 
hoogte van het ademhalingsstelsel. In de tweede plaats werd het immunogeen vermogen 
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nagegaan van recombinant tot expressie gebrachte transmembranaire proteïnen die voordien 
nog niet gekarakteriseerd werden.  
De specifieke doelstellingen van deze doctoraatsthesis waren: 
1. Het bestuderen van de systemische en mucosale immuunrespons bij varkens 
die intramusculair gevaccineerd werden met een commercieel M. hyopneumoniae-
vaccin.  
2. Het produceren van een recombinant chimeer eiwit bestaande uit drie 
adhesines van M. hyopneumoniae (P97R1, P42 en NrdF) gefuseerd met het B 
fragment van het thermolabiele enterotoxine van enterotoxigene Escherichia coli 
(LTB) en het nagaan van de capaciteit van dit chimeer eiwit om een specifieke 
immuunrespons te induceren bij muizen en varkens. 
3. Het identificeren, klonen en karakteriseren van transmembranaire proteïnen 
van M. hyopneumoniae die eventueel bruikbaar kunnen zijn voor het ontwikkelen van 
vaccins tegen enzoötische pneumonie. 
In hoofdstuk 1 wordt een literatuuroverzicht gegeven in verband met M. 
hyopneumoniae, met nadruk op vaccinatie, inclusief het principe van “reverse vaccinology”. 
De doelstellingen van deze doctoraatsthesis worden gegeven in hoofdstuk 2 en de drie 
uitgevoerde experimentele studies worden besproken in hoofdstuk 3. Tenslotte worden in de 
algemene discussie (hoofdstuk 4) de voornaamste bevindingen bediscussieerd en worden 
suggesties gegeven voor verder onderzoek. 
In de eerste experimentele studie (hoofdstuk 3.1) werd de systemische en mucosale 
immuun respons bestudeerd bij biggen die op de leeftijd van 7 dagen eenmalig intramusculair 
gevaccineerd werden met een commercieel M. hyopneumoniae bacterin. De dieren werden 
geëuthanaseerd en daarna gelijkschouwd op de leeftijd van 30, 36 en 58 dagen. 
Immunologische testen werden uitgevoerd op het bloed, longspoelvocht, de long, bronchiale 
lymfeknopen en de milt van gevaccineerde dieren en niet gevaccineerde controle varkens. Het 
serum en het longspoelvocht werden getest op de aanwezigheid van antistoffen door middel 
van ELISA. Monomorfonucleaire cellen werden uit het perifeer bloed en de weefsels 
geïsoleerd om de aanwezigheid van T-cellen na te gaan door middel van flowcytometrie. 
Tevens werd door middel van ELIspot en ELISA de cytokineproductie door deze cellen 
onderzocht. Antistoffen tegen M. hyopneumoniae werden teruggevonden in het serum van de 
meeste gevaccineerde varkens op 30 dagen leeftijd. M. hyopneumoniae specifieke IgG, IgM 
en IgA konden gedetecteerd worden in het longspoelvocht van gevaccineerde dieren, maar 
niet bij de controledieren. Significant hogere aantallen IL-12-secreterende cellen werden bij 
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de gevaccineerde dieren aangetroffen in de longen op 58 dagen leeftijd, in vergelijking met de 
niet-gevaccineerde dieren (p<0.005). Het aantal IL-10-secreterende cellen in de bronchiale 
lymfeknopen was ook hoger bij de gevaccineerde groep op 58 dagen leeftijd (p<0.05). Na 
herstimulatie van de lymfocyten uit de bronchiale lymfeknopen en de longen, werden er 
significant hogere hoeveelheden IL-12 gesecreteerd bij de gevaccineerde dieren van 58 dagen 
oud. Deze resultaten tonen aan dat het vaccin zowel een systemische als een mucosale 
cellulaire en humorale immuunrespons induceert. 
In de studie beschreven in hoofdstuk 3.2 werd een multi-antigen chimeer met drie 
adhesines van M. hyopneumoniae (R1, P42 en NrdF) en het LTB geconstrueerd. Het LTB 
fungeerde als mucosaal adjuvans. De antigene en immunogene eigenschappen werden zowel 
bij muizen als bij varkens onderzocht. Bovendien werd het gelijktijdig toedienen van de 
afzonderlijke adhesines vergeleken met het toedienen als multi-antigen chimeer. Het chimeer-
eiwit werd geconstrueerd en tot expressie gebracht in E. coli. Antistoffen gericht tegen elke 
subunit herkenden het chimeer-eiwit, wat de antigene eigenschappen van dit eiwit aantoont. 
Intranasale en intramusculaire immunisatie van muizen met het chimeer-eiwit deed het aantal 
IgG en IgA-antistoffen in respectievelijk het serum en longspoelvocht significant toenemen. 
Muizen die geïmmuniseerd werden met het chimeer-eiwit vertoonden significant hogere 
concentraties IgG- en IgA-antistoffen gericht tegen rP42 dan in het pre-immunisatieserum 
(p<0,05), zowel na intramusculaire als na intranasale immunisatie. Varkens die 
geïmmuniseerd werden met het chimeer-eiwit bouwden antistoffen op tegen alle M. 
hyopneumoniae antigenen aanwezig in het chimeer-eiwit. Dieren die geïmmuniseerd werden 
met het multi-antigen chimeer vertoonden de hoogste immuunrespons. Dit kan er op duiden 
dat een dergelijk multi-antigen chimeer een bruikbaar vaccin zou kunnen zijn. Verdere studies 
waarbij gevaccineerde varkens experimenteel besmet worden met M. hyopneumoniae zijn 
evenwel noodzakelijk om dit te bevestigen. 
De volledige genoom-sequenties van vier M. hyopneumoniae-stammen zijn 
beschikbaar. Dit maakt het mogelijk om “reverse vaccinology“ toe te passen voor de 
ontwikkeling van recombinante subunit vaccins. In de derde studie (hoofdstuk 3.3) werden 17 
genen die coderen voor transmembranaire proteïnen van M. hyopneumoniae, gekloond. Van 
deze 17 genen werden er zes succesvol tot expressie gebracht in E. coli. De immunogene en 
antigene eigenschappen van de aldus tot expressie gebrachte eiwitten werden onderzocht. Alle 
eiwitten vertoonden immunogene eigenschappen bij muizen en serum van natuurlijk 
geïnfecteerde varkens reageerde met de recombinante proteïnen. Dit suggereert dat deze 
proteïnen tot expressie worden gebracht tijdens een M. hyopneumoniae infectie. Deze 
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antigenen kunnen een bijdrage leveren tot de ontwikkeling van nieuwe recombinante vaccins 
tegen EP en diagnostische testen voor de detectie van deze ziekte. 
Als conclusie kan gesteld worden dat intramusculaire vaccinatie met een commercieel 
beschikbaar geïnactiveerd vaccin op basis van M. hyopneumoniae kiemen zowel een 
systemische als lokale immuunrespons uitlokt. Er werd ook aangetoond dat een chimeer 
vaccin bestaande uit een fusieproteïne van drie M. hyopneumoniae adhesines en het mucosaal 
adjuvans LTB, een immuun respons induceert tegenover deze drie adhesines. Dit kan er op 
duiden dat deze benadering nuttig kan zijn voor ontwikkeling van nieuwe vaccins. Ook 
recombinant tot expressie gebrachte transmembranaire proteïnen van M. hyopneumoniae 
waren immunogeen. De stabiliteit van chimere vaccins dient nog nader onderzocht te worden 
en hun doeltreffendheid moet nagegaan worden door middel van infectieproeven bij varkens. 
Verder onderzoek is ook nodig om betere inzichten te verkrijgen in de rol die de 
immuunrespons van de gastheer speelt in het verkrijgen van bescherming enerzijds en het 
induceren van letsels anderzijds.  
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